



3rd International Congress on ADHD

From Childhood to Adult Disease



26 – 29 May 2011
Berlin | Germany



www.adhd-congress.org

Table of Contents

	Page		Page
Welcome Address	4	Electricity	12
Organization	5	Lost and Found	12
Acknowledgements	5	Mobile Phones	12
Committees	6	Programme Changes	12
ICC Floor Plan	7	Climate	12
World Federation of ADHD	8	Press	12
General Assembly	8	First Aid	12
General Information		Patient's Day	12
Congress Venue	9	Insurance	12
Congress Registration Counter	9	How to get to the ICC	13
Certificate of Attendance	9	Car Park	13
Name Badges	10	Taxis	13
Congress Language	10	Supporting Programme	14
EACCME – Continuing Medical Education	10	Format Descriptions	15
Publications for Proceedings	10	Opening Ceremony	16
Internet Centre	10	Programme Overview	17
Congress Information System	10	Scientific Programme	
WLAN	10	Thursday, 26 May 2011	21
Technical Exhibition	10	Friday, 27 May 2011	24
Poster Exhibition	11	Saturday, 28 May 2011	44
Awards	11	Sunday, 29 May 2011	62
Speakers Centre	11	Satellite Symposia	64
Medical Historical Exhibition	11	Educational Goals	65
Restaurants	12	List of Exhibitors and Map	70
Coffee Breaks and Lunch	12	List of Chairpersons and Presenters	71
Cloakroom	12		
Bank	12		
Currency	12		

Welcome Address



Andreas Warnke

Dear colleagues,

In the name of the World Federation of ADHD it is our pleasure to welcome you here in Berlin to the 3rd International Congress on ADHD: From Childhood to Adult Disease for what – we are sure – will be a very enjoyable and highly informative conference. The key themes addressed will be the course of symptomatology in respect to transcultural influences, age and gender, developmental aspects of classification and co-morbidity; psychosocial and neurobiological aspects of aetiology, the latest update on genetics and neuroimaging, new findings in the psychotherapeutic and psychopharmacological treatment approaches, and features of life quality.



Manfred Gerlach

After the incredible success of the Vienna meeting 2 years ago – almost 2,000 participants from 70 countries attended – Berlin is the ideal setting to elucidate and discuss the current advances in basic science and clinical research that contribute to our understanding of ADHD as a lifespan disorder. Berlin provides a unique atmosphere of true international spirit as it is one of the most pluricultural cities in Europe attracting people from different cultural and ethnic backgrounds who peacefully live and work together. Today, the German capital is a modern, lively, vibrant, fascinating city in the centre of Europe offering a plethora of historical, cultural, scientific, architectural and other features and achievements which you will love to experience.

We are delighted to welcome internationally renowned speakers to address the exciting and important topic of ADHD in Plenary Symposia, Hot Topic Symposia, Debates, Workshops, Video Sessions, Educational Seminars and Meet-the-Experts Sessions. We are privileged to have this impressive faculty, with their wealth of global experience and expertise in ADHD research and service delivery, sharing their work with us here at this conference. In addition to the main conference programme, young talents will present their new ideas in Young Scientist Award Sessions. We are proud to have over 500 posters being presented in 41 Guided Poster Tours demonstrating the volume of research activity and evidence-based clinical practise in this field. We would like to encourage you to not only view these selected posters, but to also engage in an active discussion and exchange of ideas with our young colleagues.

Please come and enjoy the congress and the city to combine hard work with social and cultural highlights, and to come together to reinforce old friendships and create new ones as well as fruitful collaborations. But most of all, do not miss a unique opportunity to share the science that is the driving force of the World Federation of ADHD and our profession.

Thank you very much for your participation and valuable contribution.

Sincerely yours



Prof. Dr. Andreas Warnke
Congress President
President World Federation
of ADHD



Prof. Dr. Manfred Gerlach
Chair Scientific Programme
Committee

CONGRESS PRESIDENT

Prof. Dr. Andreas Warnke
Department of Child and Adolescent Psychiatry,
Psychosomatics and Psychotherapy
University of Würzburg
Füchsleinstr. 15
97080 Würzburg, Germany
Phone: +49-931-201-78010
Fax: +49-931-201-78040
Email: warnke@kjp.uni-wuerzburg.de

SCIENTIFIC CONTACT

Prof. Dr. Manfred Gerlach
Department of Child and Adolescent Psychiatry,
Psychosomatics and Psychotherapy
University of Würzburg
Füchsleinstr. 15
97080 Würzburg, Germany
Phone: +49-931-201-78010
Fax: +49-931-201-77680
Email: manfred.gerlach@kjp.uni-wuerzburg.de

CONGRESS VENUE

International Congress Center ICC Berlin
Neue Kantstraße/Messedamm
14057 Berlin, Germany
www.icc-berlin.de

ORGANIZER

World Federation of ADHD
Global Head Office
CPO HANSER SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: adhd@cpo-hanser.de

**Verein zur Durchführung
Neurowissenschaftlicher Tagungen e.V.**
Paulsborner Str. 44
14193 Berlin, Germany

CONGRESS AND EXHIBITION OFFICE

**CPO HANSER[®]
SERVICE**
CPO HANSER SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: adhd2011@cpo-hanser.de

Acknowledgements

The organizers of the 3rd International Congress on ADHD gratefully acknowledge the support of the following companies (as per May 2011):

PRINCIPLE SPONSORS

Shire 

MAJOR SPONSORS

Janssen
Pharmaceutica NV 

Eli Lilly
and Company 

Committees

SCIENTIFIC PROGRAMME COMMITTEE

Chair: M. Gerlach, Germany
S. F. Ali, USA
T. Banaschewski, Germany
J. Buitelaar, The Netherlands
F. X. Castellanos, USA
S. C. Cho, Republic of Korea
D. Coghill, United Kingdom
J. Deckert, Germany
M. Döpfner, Germany
S. Faraone, USA
J. M. Fegert, Germany
A. Fossati, Italy
C. Freitag, Germany
R. R. Gainetdinov, USA
L. Greenhill, USA
D. A. Hay, Australia
J. Hebebrand, Germany
B. Herpertz-Dahlmann, Germany
M. Huss, Germany
S. Kasper, Austria
R. Klein, USA
S. Kooij, The Netherlands
C. J. Kratochvil, USA
K. Lange, Germany
J. O. Larsson, Sweden
G. Lehmkuhl, Germany
K.-P. Lesch, Germany
A. Miranda, Spain
M. Muenke, USA
O. O. Omigbodun, Nigeria
H. Ozawa, Japan
P. Pauli, Germany
A. Philipsen, Germany
F. W. Reimherr, USA
H. Remschmidt, Germany
P. Riederer, Germany
M. Rösler, Germany
L. A. Rohde, Brazil

A. Rothenberger, Germany
K. Rubia, United Kingdom
P.-A. Rydelius, Sweden
T. Saito, Japan
S. Shirataki, Japan
A. Seif El Din, Egypt
E. Sonuga-Barke, UK
R.-D. Stieglitz, Switzerland
Y. Taneli, Turkey
R. Tannock, Canada
E. Taylor, United Kingdom
J. Thome, Germany
O. Tucha, The Netherlands
A. Vetro, Hungary
R. Vermeiren, Belgium
S. Walitza, Switzerland
A. Warnke, Germany
M. Weiss, Canada
T. E. Wilens, USA
E. Wolters, The Netherlands
Y. Zheng, China
A. Zuddas, Italy


LOCAL ORGANIZING COMMITTEE

Chair: A. Warnke, Würzburg, Germany
U. Lehmkuhl, Berlin, Germany
A. Heinz, Berlin, Germany
I. Heuser, Berlin, Germany


POSTER PRIZE COMMITTEE

Chair: A. Kutzelnigg, Austria
C. Bachmann, Germany
M. Colla, Germany
A. Ströhle, Germany
M. Romanos, Germany

ICC – Floor Plan



Stand/as of 2009/06



World Federation of ADHD founded

In August 2008, the World Federation of ADHD (Attention Deficit Hyperactivity Disorder) and allied disorders was founded in Zurich, Switzerland. Prof. Dr. Andreas Warnke, Director of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Würzburg, Germany was officially nominated the first president of this non-profit organisation.

ADHD is a highly heritable childhood-onset psychiatric condition which is characterized by age-inappropriate levels of the core symptoms inattention, hyperactivity and impulsivity. The disorder affects about 5 % of children worldwide. Recent scientific studies in ADHD reveal biological underpinnings such as multiple genetic factors, ADHD-related differences in brain structure and function, as well as changes in neurotransmitter components within the basal ganglia thalamocortical neurocircuitries. The purpose of the World Federation of ADHD and allied disorders is to support and promote clinical studies, scientific projects and training programmes in the field of ADHD and related disorders worldwide, as well as to enhance the exchange of information between scientists, physicians, health experts, ADHD lay organisations, and the public. As one of the major tools to achieve these goals, the International Congress on ADHD, which is now in its third successful year, was launched.

World Federation of ADHD, Global Head Office

CPO HANSER SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany

Phone: +49-40-670 88 20
Fax: +49-40-670 32 83
Email: adhd@cpo-hanser.de

General Assembly

27.5.2011, 13.00 – 14.00 h, Hall 6



4th International Congress on ADHD
From Childhood to Adult Disease

6 – 9 June 2013
Milan, Italy

CONGRESS VENUE

International Congress Center ICC Berlin
Neue Kantstraße/Messedamm
14057 Berlin, Germany
www.icc-berlin.de

CONGRESS REGISTRATION COUNTER

All congress materials and documentation will be available from the congress registration counter located at the entrance level of the ICC Berlin.

Opening Hours

Thursday, 26 May 2011	10:00–19:00 h
Friday, 27 May 2011	07:15–18:00 h
Saturday, 28 May 2011	07:15–17:30 h
Sunday, 29 May 2011	07:30–13:30 h

During these opening hours the congress counter can be reached at:

Phone: +49–30–3038-8198-1

Fax: +49–30–3038-81980

The congress counter will be divided into the following sections:

On-site-registration

On-site registration for the congress.

Pre-registration paid

Participants who have already registered and paid for the congress will receive their documents here.

Pre-registration unpaid

Participants who have already registered for the congress, but not paid yet, will receive their documents here.

World Federation of ADHD

Information about the World Federation of ADHD and membership will be given here.

Hotels and Tours

Assistance for the reservation of hotel rooms or tours in Berlin will be provided.

REGISTRATION FEES

Registration and Payment	from 2 April 2011
Non member from Countries A ¹	EUR 500
Non member from Countries B ¹	EUR 400
Member World Federation of ADHD from Countries A ¹	EUR 450
Member World Federation of ADHD from Countries B ¹	EUR 350
Students and persons under 35 years*	EUR 350
Accompanying persons	EUR 80
Educational Seminars**	EUR 30
Meet the Expert-Sessions**	EUR 30

¹⁾ For list of countries A and B, please check the congress website or ask at the counter.

* A copy of the passport and student identity card is necessary.

** Only valid in combination with the congress registration fee.

Registration fee for the participants includes:

- ➔ Admission to all scientific sessions
- ➔ Admission to poster and technical exhibition
- ➔ Conference materials (delegate bag, final programme, abstract book, etc.)
- ➔ Admission to the Opening Ceremony and Welcome Reception on Thursday
- ➔ Coffee breaks and light lunch from Thursday to Sunday

Registration fee for accompanying persons includes:

- ➔ Admission to the Opening Ceremony on Thursday
- ➔ A city sightseeing tour

On-site registration

On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of congress bags may be limited.

CERTIFICATE OF ATTENDANCE

Please hand in your evaluation form at the counter for a certificate of attendance.

General Information

NAME BADGES

All participants are requested to wear their name badge at all times during the congress. The colours of the name badges have the following significance:

Delegate:	red
Accompanying person:	rose
Exhibitor:	green

CONGRESS LANGUAGE

The congress language is English. Simultaneous translations will not be provided.

EACCME – CONTINUING MEDICAL EDUCATION

The 3rd International Congress on ADHD is accredited by the European Accreditation Council for Continuing Education in Brussels (EACCME), an institution of the UEMS, to provide EACCME credits for the attendance at the scientific sessions of the core programme as well as for the educational seminars.

The 3rd International Congress on ADHD is designated for a maximum of 16 CME credit points of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Moreover, the congress has been accredited with the following CME credit points from the medical chamber (Landesärztekammer) Berlin:

Half day: 3 credit points
Full day: 6 credit points
Total: 21 credit points

Please hand in the evaluation form enclosed in the congress bag to receive a printed copy of the accreditation certificate.

PUBLICATIONS FOR PROCEEDINGS

The organizer of the congress retains the right to publish all material presented at the congress in any congress publication.

INTERNET CENTRE

Internet terminals are available to all delegates in the exhibition area on the lobby level of the ICC. The Internet Centre is accessible according to the opening hours of the exhibition.

CONGRESS INFORMATION SYSTEM CO CONGRESS ONLINE®

www.adhd-congress.org

Participants can benefit from the web based ADHD Congress Information System CO CONGRESS ONLINE® on-site. They can set up and print out a personal congress programme schedule.

The ADHD Congress Information System provides information on:

- Updated scientific programme
- Programme by day
- Programme by formats with accepted abstracts of chairpersons and speakers
- Programme search
- List of participants (who is who)
- List of exhibitors
- General congress information
- Private mail box

WLAN

Free WLAN access is available in all lobbies. The networks name is: "ICC WIFI". The password is: "ADHD2011".

TECHNICAL EXHIBITION

The 3rd International Congress on ADHD will be accompanied by a technical exhibition taking place on the lobby level in the central lobby of the ICC Berlin. Coffee bars are located in the vicinity of the technical exhibition.

Opening hours

Thursday, 26 May 2011	15:00–20:00 h
Friday, 27 May 2011	09:00–17:00 h
Saturday, 28 May 2011	09:00–17:00 h
Sunday, 29 May 2011	09:00–13:00 h

POSTER EXHIBITION

The poster exhibition of the 3rd International Congress on ADHD is located in the main lobby on the first floor (lobby level) of the ICC Berlin. Posters are allocated to 41 guided poster tours (P-01 to P-41). Posters will be changed daily and are on display for the entire day of the related poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all participants:

Poster Exhibition Times for P-01 to P-21

Friday, 27 May 2011	09.00 – 17.00 h
Guided Poster Tour	14.30 – 16.00 h

Poster exhibition Times for P-22 to P-41

Saturday, 28 May 2011	09.00 – 17.00 h
Guided Poster Tour	14.30 – 16.00 h

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set up times for posters

Poster Tour P-01 to P-21

Set up:	Thursday, 26 May 2011	15.00 – 19.00 h
	Friday, 27 May 2011	09.00 – 12.00 h
Dismantling:	Friday, 27 May 2011	16.00 – 18.00 h

Poster Tour P-22 to P-41

Set up:	Saturday, 28 May 2011	09.00 – 11.00 h
Dismantling:	Sunday, 29 May 2011	09.00 – 13.00 h

Posters which have not been removed within the indicated time schedule will be removed and disposed of. The poster size is 150 cm high and 95 cm wide (Portrait format).

AWARDS

Scientists have been encouraged to hand in their abstracts and apply for the following awards:

Poster Awards

All posters will be evaluated on site and the best of each poster tour will be displayed on separate poster walls after the tours. On Sunday, May 26th 2011, the best six posters will be selected out of all poster tours by the poster prize committee. Those posters will be awarded with a poster prize of EUR 500 each. The award ceremony will take place during the Closing Ceremony on the last congress day.

Young Scientists Awards

Young Scientists Sessions aim at encouraging young scientists to attend this interdisciplinary congress in the field of ADHD. The sessions will be composed of 20 minutes lectures. Eight young scientists' abstracts have been chosen by the scientific committee out of 200 applications for two sessions à four presenters. The sessions will be chaired by recognized experts for the featured topic. Speakers are requested to show via copy of their ID that they are younger than 40 years of age. The winners will receive a young scientist award of EUR 300 each and a free registration.

SPEAKERS CENTRE

The speakers centre is located next to the counter at the entrance level of the ICC. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation but at the latest 90 minutes prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the speakers centre where speakers can also work on their charts in a quiet area. Technical staff will be glad to assist.

operated by **ESTENSIS**
The Conference Company.

Estensis GmbH – the Conference Company

Opening Hours

Thursday, 21 May 2011	10.00 – 18.00 h
Friday, 22 May 2011	07.15 – 18.30 h
Saturday, 23 May 2011	07.15 – 18.00 h
Sunday, 24 May 2011	07.30 – 13.00 h

MEDICAL HISTORICAL EXHIBITION

A short history of ADHD – An historical overview on major achievements in research and therapy

This medical historical exhibition presents major achievements in research and therapy and honours major therapeutical contributions. Starting with the work of Heinrich Hoffmann, it features early contributions of George Frederick Still, Alfred Tredgold, Charles Bradley and Kramer/Polinow as well as modern developments and the quest for new therapeutical approaches.

Dedicated to Prof. Dr. Andreas Warnke.

General Information

RESTAURANTS

Some restaurants are in walking distance of the congress venue and snack stations can be found within the exhibition area of the ICC.

COFFEE BREAKS AND LUNCH

Coffee and tea are served during the morning and afternoon coffee breaks from Thursday afternoon, 26 May to Sunday, 29 May 2011, free of charge to all registered participants. Additional coffee stations are located in the exhibition area of the ICC and at the entrance level next to the registration counter. A healthy lunch buffet will be served on Friday and Saturday to registered delegates.

CLOAKROOM

A cloakroom is available next to the registration counter on the ground floor. You can also store your luggage there. Price per item: EUR 1,70 per coat/EUR 2,30 per luggage item.

BANK

An ATM/cash machine is located within the entrance area of the ICC.

CURRENCY

The official German currency is Euro. Exchange of foreign currency is available at Berlin Airport and at most hotels, banks and exchange offices throughout the city.

ELECTRICITY

Germany uses a 230 volt 50 Hz system. Sockets have the European standard and plugs are two-prong grounded.

LOST AND FOUND

A lost and found service is available at the Information Counter of the ICC located on the entrance level of the congress venue.

MOBILE PHONES

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

PROGRAMME CHANGES

The organizers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances.

CLIMATE

Berlin's climate is usually mild during the early summer months. At end of May, the average temperature is between 17°C (68°F) and 23°C (77°F) during the day. Fluctuation between day and night temperatures is about 10°C (50°F).

PRESS

Journalists should bring their valid press ID and register at the registration counter on the entrance level of the ICC.

FIRST AID

First aid is provided at the South East entrance. Counter staff is able to show the way.

PATIENT'S DAY

As in the former years, a patient's day will take place during the congress. This time, the patient's day will be held on Saturday, May 28, 2011, from 14.30 – 18.30 h.

The venue

Campus Virchow Klinikum
Augustenburger Platz 1
13353 Berlin

INSURANCE

The congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of origin.

HOW TO GET TO THE CONGRESS VENUE

Berlin has two airports, Berlin Tegel, which is located in the North-West of the city, and Berlin Schönefeld, which is in the South-East.

From Airport Tegel

Bus X9 (Express) or Bus 109: in direction of Zoologischer Garten, to stop S-Bahn or Jungfernheide, change in S42 (Ringbahn) in direction Westend, to stop Messe Nord/ICC.

From Airport Schönefeld

S9 in direction of Bahnhof Blankenburg to stop Ostkreuz, change into S3, S5, S75 to stop Westkreuz or Messe Süd.

From railway stations to exhibition grounds/ICC Berlin

Railway station Zoologischer Garten, railway station Charlottenburg, railway station Ostbahnhof und railway station Lichtenberg – exhibition grounds/ICC Berlin

➔ S 3, S 5, S 75 in direction Westkreuz/Olympiastadion/Spandau, to stop Westkreuz or Messe Süd

Railway station Schönefeld – exhibition grounds/ICC Berlin

➔ RE 7, RB 14, S 9 in direction of Ostkreuz, then change into S 3, S 5, S 75 to stop Westkreuz or Messe Süd

Railway station Spandau – exhibition grounds/ICC Berlin

➔ S 3 in direction of Erkner, to stop Messe Süd

➔ S 75 in direction of Wartenberg, to stop Messe Süd

Railway station Potsdam – exhibition grounds/ICC Berlin


➔ S 7 in direction Ahrensfelde, to stop Westkreuz

CAR PARK

Parking space is available next to the ICC Berlin and participants arriving by car are advised to use these facilities. Parking fees are not included in the registration fee. A daily ticket costs EUR 7,50.

TAXIS

A taxi stand is located on the lower level of the ICC Berlin. Participants can call taxis at the ICC information counter in the entrance foyer.



Supporting Programme

Tours available will be assigned on a first-come, first served basis. We ask you to make your reservation at the congress counter. All tours will start and end at the ICC Berlin in front of the entrance.

SUPER CITY SIGHTSEEING TOUR OF BERLIN

Friday, 27.05.2011 **14.00 – 17.00 h**
and Saturday, 28.05.2011 **14.00 – 17.00 h**
(depending on number of participants)

Starting and end point: ICC

A city guide will introduce you to the city and explain its former unique status and its new situation. The bus tour will take through East and West Berlin, showing the most important sites like Potsdamer Platz, Checkpoint Charlie, Humboldt University, Museum Island and Brandenburg Gate. You will also pass the Russian memorial statue and get an overview of the newly built German Government area including the Reichstag.

Price per person: EUR 25,00

For registered accompanying persons this tour is complimentary and necessary to reserve prior to the congress. Please come to the registration counter to book this tour.

BERLIN FROM SPREE CANALS

Saturday, 28.05.2011 **13.30 – 16.00 h**

Starting and end point: ICC

Berlin was once Germany's second largest inland port. And the city still has more bridges than Venice! Travel by coach to the landing pier Schlossbrücke. There you will board a public sightseeing boat. See Berlin from an unusual and fascinating perspective during this cruise through some of the Spree River canals. You will see Charlottenburg Palace, then travel along the Spree to Berlin-Mitte, the historic heart of the city. Pass such famous sights as the Reichstag, the Berlin Cathedral and the Museum Island, site of one of the world's richest museum complexes, and the Nikolai Quarter. From here, a bus brings you back to the ICC.

Price per person: EUR 37,00



Hackesche Höfe

PLENARY SESSIONS (PS)

Duration: 90 or 120 min.

Plenary sessions will feature authoritative scientific updates on a comprehensive range of topics. Each daily session is composed of three to four 30 minute lectures presented by international leaders in the field of ADHD.

HOT TOPIC SYMPOSIA (HT)

Duration: 90 min.

Parallel symposia will feature comprehensive reviews of the most recent research results as well as practical issues in the field of ADHD. Each symposium of 90 minutes contains a theme of topical interest and is composed of three or four lectures presented by internationally recognized clinicians and neuroscientists. Discussions welcome.

EDUCATIONAL SEMINARS (ES)

Duration: 45 min.

Educational Seminars are designed to be informal and interactive and will feature an update of current knowledge on clinical relevant topics. Each 45 minute seminar is composed of one or two lectures followed by a discussion. To facilitate discussions, attendance is limited. Therefore it is recommendable to book the ticket online already with the congress registration or to check ticket availability on site at the registration counter. Tickets are handled on a first-come, first-served basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

MEET THE EXPERT SESSIONS (ME)

Duration: 45 min.

These interactive sessions have been organized to cover a variety of ADHD related topics. The aim is to provide an informal atmosphere where doctors and researchers can interact with experts in their fields, who will give their undivided attention for an hour. Knowledge, insight and first hand learning about the latest advancements will be possible. The sessions will be open to all but strictly on a first-come, first-served basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

GUIDED POSTER TOURS (P)

Duration: 90 min.

All accepted poster abstracts will be presented during these tours. All expected posters will be sorted by topics and presented during guided tours. Posters will be changed daily and are on display for the entire day of the related day. Information regarding poster format, set-up and dismantling has been sent to the authors with their notification of abstract acceptance.

VIDEO SESSION (VS)

Duration: 90 min.

The Video Session will last 90 minutes. Two Chairpersons, experts in the field of neurology and psychiatry, will present videos of scientific issues and will discuss the diagnosis with participants.

YOUNG SCIENTIST AWARD SESSIONS (YS)

Duration: 90 min.

Young Scientist Sessions aim at encouraging young scientists to attend these interdisciplinary congresses in the field of ADHD. The sessions are composed of 20 minutes lectures plus discussion. The sessions will be chaired by recognized experts for the featured topic. Speakers must be younger than 40 years of age.

WORKSHOPS (WS)

Duration: 90 min.

During workshops leading experts in the field of ADHD research held discussions with the attendees. These meetings are aimed at a specific, interactive and limited audience.

PRO AND CONTRA DEBATE (PCD)

Duration: 90 min.

Two experts discuss controversial aspects to an up-to-date topic within the field of ADHD.

SATELLITE SYMPOSIA

Duration: 60 – 90 min.

Satellite symposia will be organized by pharmaceutical companies and are open to all congress delegates.

Thursday, 26 May 2011

19.00 h, Hall 2, ICC Berlin

Welcome to Berlin

Moderator: Dr. Jakob Hein, Berlin, Germany

Welcome Address

Professor Dr. Andreas Warnke, Würzburg, Germany, Congress President
Professor Dr. Ulrike Lehmkuhl, Berlin, Germany, Local Organizing Committee

Music by Männerwirtschaft – Music from the Comedian Harmonists

Florian Stern (1. Tenor)

Christoph Kalz (2. Tenor)

Julian Hirsch (Baritone)

Oliver Zimmer (Bass)

Alexander Fleischer (Piano)

Veronika, der Lenz ist da

Wenn die Sonja russisch tanzt

Schöne Isabella von Kastilien

Opening Lecture

Introductory remarks: Professor Eric Taylor, London, United Kingdom

Professor Dr. Margeret Weiss, Vancouver, Canada

CHAOS: The child health ADHD observational study

Männerwirtschaft – Music from the Comedian Harmonists

Wochenend und Sonnenschein

Ich wollt', ich wär ein Huhn

Mein kleiner grüner Kaktus

Männerwirtschaft – enjoy music from the times of the Comedian Harmonists

Five Berlin musicians form the ensemble Männerwirtschaft and fascinate many with their unique A Capella style. They will perform authentically classics from the original assembly, the Comedian Harmonists. Those were an internationally famous, all-male German ensemble that performed in the 1920s' and 1930s' as one of the most successful musical groups in Europe before World War II. The hallmark of the Comedian Harmonists was its members' ability to blend their voices together so that the individual singers could appear and disappear back into the vocal texture. Its repertoire was wide, ranging from the folk and classical songs arranged by Frommermann to appealing and witty popular songs of the day by writers such as Peter Igelhoff, Werner Richard Heymann and Paul Abraham (composer).

Welcome Reception and Get-Together

At the end of the Opening Ceremony all participants are invited to join the Welcome Reception in the exhibition area of the ICC Berlin. Light snacks and beverages will be provided.

Programme Overview – Thursday, 26 May 2011

Room Time	Hall 2	Hall 3	Hall 4/5	Hall 6	Hall 7	Hall 8	Entrance and Lobby Level
12.00							Registration 10.00–19.00 h on the Entrance Level
13.00							
14.00	HT-01 IMpACT symposium on adult ADHD	HT-02 Reward processing in children and adults with ADHD	WS-01 ADHD and forensic psychiatry	WS-02 Cell culture experi- ments in ADHD	HT-03 Progress in under- standing and treat- ment of ADHD – a neurobiological perspective	WS-03 Long-term effects of medication and psychotherapy in patients with ADHD	Technical Exhibition 15.00–20.00 h in the Central Lobby
15.00	HT-05 Networking the adult networks	HT-06 International Col- laboration on ADHD and substance abuse	HT-07 Structural, func- tional and neuro- chemical correlates of adult ADHD: Do they differ from childhood?		HT-04 Biomarker candidates for the diagnosis, long-term course and therapeutic management of ADHD		
16.00	Coffee Break			SA-05 Medical treatment of adults with ADHD (MEDICE)	Coffee Break		
17.00		SA-01 ADHD and adolescents (Eli Lilly and Company)					
18.00							
19.00							
20.00	Opening Ceremony						

Abbreviations

PS	Plenary Session	ME	Meet the Experts-Session
SA	Satellite Symposium	HT	Hot Topic Symposium
WS	Workshop	YS	Young Scientist Award Session
ES	Educational Seminar	V	Video Session
P	Guided Poster Tour	PCD	Pro and Contra Debate

Friday, 27 May 2011 – Programme Overview

Room Time	Hall 2	Hall 3	Hall 4/5	Hall 6	Hall 7	Hall 8	Salon 11/12	Salon 13/14	Entrance and Lobby Level
07.30									Registration 7.15–18.00 h on the Entrance Level
08.00			ES-01 Organisation and carrying out of parent...	ES-02 ADHD and substance abuse...	ES-03 Comorbid disorders or attention-...	ME-01 Diagnosis of ADHD	ME-02 Pathogenesis of ADHD	ME-03 Pharmacologi- cal treatment of ADHD	
09.00	PS-01 Update on diagnosis, classification and aetiology of ADHD in childhood, adolescence and adulthood								Technical Exhibition 9.00–17.00 h in the Central Lobby
10.00									
11.00	Coffee Break								
12.00	PS-02 Update on neurobiology of ADHD								
13.00	Lunch Break	SA-02 ADHD in Ado- lescents (Janssen Phar- maceutica NV)	General Assembly of ADHD		Lunch Break				
14.00									
15.00									Guided Poster Tours P-01 – P-21 in the Main Lobby
16.00	Coffee Break								
17.00	HT-08 Next steps towards empirically supported psychosocial treatments for adult ADHD	HT-11 Interna- tional ADHD treatment guidelines for childhood, adolescence and adulthood	HT-10 Emotional symptoms in ADHD: Part of the disorder?	HT-09 KFO 125 ADH D	HT-12 ADHD and conduct disorder from childhood to adulthood	YS-01 Young Sci- entist Award Session			
18.00		SA-03 PUFAs and ADHD – More than an hypot- hesis? (Vifor Pharma)							
19.00									

Programme Overview – Saturday, 28 May 2011

Room Time	Hall 2	Hall 3	Hall 4/5	Hall 6	Hall 7	Hall 8	Salon 11 / 12	Salon 13 / 14	Salon 1516	Entrance and Lobby Level	
07.30										Registration 7.15–17.30 h on the Entrance Level	
08.00			ES-04 Diagnostic assessment of ADHD...	ES-05 Neurofeed- back in the doctor's office	ES-06 Differential diagnosis of adult ADHD	ES-07 Psychometric assessment of adult ADHD	ME-04 Guidelines	ME-05 ADHD over the lifetime	ME-06 Treatment of adult ADHD		
09.00	PS-03 Course, dif- ferential di- agnosis and co-morbidity of ADHD									Technical Exhibition 9.00–17.00 h in the Central Lobby	
10.00											
11.00	Coffee Break										
12.00	PCD-01 The psycho- stimulant is not danger- ous for the patients										
13.00		SA-04 The Diversity of ADHD (Shire)	Lunch Break								
14.00											
15.00										Guided Poster Tours P-22 – P-41 in the Main Lobby	
16.00	Coffee Break										
17.00	HT-13 Non-phar- macologic interven- tions for the treatment of ADHD	HT-14 Impact of ADHD on the risk for delinquent behaviour	HT-16 Pharmaco- imaging in ADHD	HT-15 Circadian rhythmic- ity in ADHD patients through life time	VS-01 Neuropsy- chiatric movement disorders in children, adolescents and adults	YS-02 Young Sci- entist Award Session II					
18.00											
19.00											

Sunday, 29 May 2011 – Programme Overview

Room Time	Hall 2	Hall 4/5	Hall 6	Hall 7	Hall 8	Salon 11/12	Salon 13/14	Salon 1516	Entrance and Lobby Level
07.30									Registration 7.30–13.30 h on the Entrance Level
08.00		ES-08 Therapy of co-morbid disorders in child and...	ES-09 Therapy of co-morbid disorders in adult ADHD	ES-10 Dialectical behavioural therapy-based treatment in...	ES-11 Coaching in adult ADHD	ES-12 Molecular neuroimaging in adult ADHD: ...	ES-13 Evidenced- based treatment of child and...	ES-14 The neurocog- nitive basis of ADHD – from cognitive...	
09.00	PS-04 Update on treatment of ADHD in childhood, adolescence and adults								Technical / Poster Exhibition 9.00–13.00 h in the Central / Main Lobby
10.00									
	Coffee Break								
11.00	PS-05 Persistence of ADHD: Brain imaging, genetics and treatment								
12.00									
13.00	Closing Ceremony								



Scientific Programme – Thursday, 26 May 2011

HT-01 Hot Topic Symposium

13.00–14.30 h Hall 2

IMpACT symposium on adult ADHD

Chairpersons: K.-P. Lesch, Germany
B. Franke, The Netherlands

HT-01-01 Brachiating along the developmental trajectory—on the persistence of intermediate ADHD phenotypes
B. Franke, The Netherlands

HT-01-02 Measuring the heritability of adult ADHD
P. Asherson, United Kingdom

HT-01-03 You can always blame your mother: How maternal genotype contributes to offspring ADHD
J. Haavik, Norway

HT-01-04 Expanding the phenotype-shared risk genes for bipolar disorder and adult ADHD
A. Reif, Germany

HT-02 Hot Topic Symposium

13.00–14.30 h Hall 3

Reward processing in children and adults with ADHD

Chairpersons: A. Ströhle, Germany
K. Rubia, United Kingdom

HT-02-01 Reward processing in children with Attention Deficit Hyperactivity Disorder—a comparison between drug-naïve and methylphenidate-treated subjects and healthy controls
V. Jucksch, Germany

HT-02-02 Reward processing in male adults with childhood ADHD – a comparison between drug-naïve and methylphenidate-treated subjects
M. S. Stoy, Germany

HT-02-03 A reward task for simultaneous EEG-fMRI-neuroimaging: Pilot results for a study with ADHD children
I. Wolf, Germany

HT-02-04 Altered reward processing in ADHD: Information from fMRI and NIRS
A. Fallgatter, Germany

HT-03 Hot Topic Symposium

13.00–14.30 h Hall 7

Progress in understanding and treatment of ADHD—a neurobiological perspective

Chairpersons: A. Rothenberger, Germany
H.-C. Steinhausen, Switzerland

HT-03-01 Neuronal inhibition and its modulation by TMS—neurotherapeutic perspectives for ADHD
S. Bender, Germany

HT-03-02 Candidate genes in ADHD—the importance to elucidate differential functional effects
T. Renner, Germany

HT-03-03 Neural correlates of processing emotional stimuli in children and adolescents with ADHD: A fMRI study on serotonergic modulation
F. Zepf, Germany

WS-01 Workshop

13.00–14.30 h Hall 4/5

ADHD and forensic psychiatry

Moderators: M. Rösler, Germany
W. Retz, Germany
S. Young, United Kingdom

Scientific Programme – Thursday, 26 May 2011

WS-02 Workshop

13.00–14.30 h Hall 8

Cell culture experiments in ADHD

Moderators: E. Grünblatt, Switzerland
A. Ludolph, Germany

WS-03 Workshop

13.00–14.30 h Hall 6

Long-term effects of medication and psychotherapy in patients with ADHD

Moderators: D. Eich-Höchli, Germany
G.-E. Trott, Germany

HT-04 Hot Topic Symposium

14.30–16.00 h Hall 7

Biomarker candidates for the diagnosis, long-term course and therapeutic management of ADHD

Chairpersons: M. Gerlach, Germany
M. Romanos, Germany

HT-04-01 Neuropsychological assessment
O. Tucha, The Netherlands

HT-04-02 Olfaction in ADHD and comorbid disorders
M. Romanos, Germany

HT-04-03 Transcranial brain sonography in children and adults with hyperkinetic movement disorders
J. Buchmann, Germany

HT-04-04 Biomarker Research – mRNA and protein expression analyses
R. Taurines, Germany

HT-05 Hot Topic Symposium

14.30–16.00 h Hall 2

Networking the adult networks

Chairpersons: S. Kooij, The Netherlands
M. Weiss, Canada

HT-05-01 CADDRA, the Canadian network
M. Weiss, Canada

HT-05-02 The European network adult ADHD
P. Asherson, United Kingdom

HT-05-03 The Latin American network
E. Barragan, Mexico

HT-05-04 APSARD, the USA network
A. Rostain, USA

HT-06 Hot Topic Symposium

14.30–16.00 h Hall 3

International Collaboration on ADHD and substance abuse (ICASA, www.adhdandsubstanceabuse.org)

Chairpersons: D. Hay, Australia
G. van de Glind, The Netherlands

HT-06-01 ADHD and substance abuse: Clinical and pharmacological perspectives
W. van den Brink, The Netherlands

HT-06-02 ADHD and substance abuse: A genetic perspective
J. A. Ramos-Quiroga, Spain

HT-06-03 ADHD and substance abuse: A longitudinal perspective
R. G. Klein, USA

HT-06-04 ADHD and substance abuse: Challenges for harm minimisation
S. Kaye, Australia

Scientific Programme – Thursday, 26 May 2011

HT-07	Hot Topic Symposium
14.30–16.00 h	Hall 4/5
Structural, functional and neurochemical correlates of adult ADHD: Do they differ from childhood?	
Chairpersons: L. Tebartz van Elst, Germany A. Fallgatter, Germany	
HT-07-01	Structural correlates of adult ADHD: Do they differ from childhood ADHD? K. Konrad, Germany
HT-07-02	Neurochemical findings using MR spectroscopy. Similarities and differences in childhood and adult ADHD E. Perlov, Germany
HT-07-03	Multimodal functional brain imaging in ADHD: Do we have reliable markers of ADHD dysfunction? A. Fallgatter, Germany
HT-07-04	Fear acquisition and extinction in adult ADHD: A simultaneous conditioning & fMRI study. Is there a specific pattern of dysfunctional emotional learning in ADHD across the life span? L. Tebartz van Elst, Germany
16.00–17.00 h	Coffee Break

Opening Ceremony

19.00–20.45 h

Hall 2

followed by a Welcome Reception

All participants are invited to join the Get-Together. Light snacks and beverages will be provided.



Scientific Programme – Friday, 27 May 2011

ES-01 Educational Seminar

07.45–08.30 h Hall 4/5

Organisation and carrying out of parent training
Chairperson: C. Neuhaus, Germany

ES-02 Educational Seminar

07.45–08.30 h Hall 6

ADHD and substance abuse: Problems and pitfalls in early identification and in treatment
Chairperson: D. Hay, Australia

ES-03 Educational Seminar

07.45–08.30 h Hall 7

Comorbid disorders or attention-deficit-spectrum disorders? What is the relationship between ADHD and Asperger's syndrome?
Chairpersons: L. Tebartz van Elst, Germany
F. Poustka, Germany

ME-01 Meet the Experts

07.45–08.30 h Hall 8

Diagnosis of ADHD
Expert: L. A. Rohde, Brazil

ME-02 Meet the Experts

07.45–08.30 h Salon 11/12

Pathogenesis of ADHD
Expert: S. Faraone, USA

ME-03 Meet the Experts

07.45–08.30 h Salon 13/14

Pharmacological treatment of ADHD
Expert: L. Greenhill, USA

Please book your ticket for the Educational Seminar and the Meet the Experts-Sessions in advance at the registration counter due to limited number of participants. Only valid in combination with the congress registration fee.

Fee per course: EUR 30

PS-01 Plenary Session

08.30–10.30 h Hall 2

Update on diagnosis, classification and aetiology of ADHD in childhood, adolescence and adulthood

Chairpersons: A. Warnke, Germany
L. A. Rohde, Brazil

PS-01-01 Key clinical developments relating to the diagnosis of ADHD

L. A. Rohde, Brazil

PS-01-02 Different psychopathological dimensions in adult ADHD

M. Rösler, Germany

PS-01-03 Are sensation seeking and hyperactivity in both ADHD and mania reflecting an autoregulatory attempt to stabilize wakefulness (vigilance)?

U. Hegerl, Germany

PS-01-04 Environmental influences in ADHD

J. Buitelaar, The Netherlands

10.30–11.00 h

Coffee Break

PS-02 Plenary Session

11.00–12.30 h Hall 2

Update on neurobiology of ADHD

Chairpersons: S. Walitza, Switzerland
A. Rothenberger, Germany

PS-02-01 Genetic contribution to the development of ADHD: Current state of the art

B. Franke, The Netherlands

PS-02-02 Imaging brain structure and function in ADHD

U. Müller, United Kingdom

PS-02-03 Neurophysiology of ADHD

T. Banaschewski, Germany

12.30–14.00 h

Lunch Break

Scientific Programme – Friday, 27 May 2011

General Assembly of the World Federation of ADHD

13.00–14.00 h

Hall 6

for members only

P-01 Guided Poster Tour

14.30–16.00 h

Main Foyer

Diagnosis: Children and adolescents I

Chairpersons: R. Taurines, Germany
M. Danckaerts, Belgium

P-01-01 Attention Deficit Hyperactivity subtypes: Comorbidity, treatment response and parental characteristics

O. Oner, Turkey
P. Oner, E. Cop, K. Munir

P-01-02 Comparison between parental SNAP-IV, teacher's SNAP-IV and T.O.V.A. in regards to attention and impulsivity in children with ADHD

V. Hercigonja-Novkovic, Croatia
D. Kocijan-Hercigonja

P-01-03 Validity of the DSM-IV factor structure of ADHD in young adults

D. Baeyens, Belgium
L. Van Dyck, M. Danckaerts

P-01-04 An experiential qualitative diagnosis instrument for self-image in ADHD children

G. Cucu-Ciuhan, Romania

P-01-05 When appearances can deceive: Final diagnoses of children and adolescents presenting with inattentive, hyperactive or impulsive symptoms in an out-patient child psychiatric unit

E. Lordou, Cyprus
A. Lordos, C. Lazarou, A. Lazarou, P. Mama,
A. Paradeisioti

P-01-06 The relationship of IVA and CBCL in the diagnosis of ADHD

R. Rostami, Iran
A. Rahimi, S. Ramezanzadeh

P-01-07 The strength-based interview of beha- viors, parent edition: Inter-rater rela- bility and factor structure

P. Robaey, Canada
R. Schachar, N. Forget-Dubois, G. Dionne,
M. Boivin

P-01-08 Qualitative approach to ADHD symptoms interpretation: Implications for differ- ential diagnostics

K. Romstein, Croatia

P-01-09 The relationship of CAS and CBCL in the diagnosis of ADHD

R. Rostami, Iran
M. Imani, M. Rajabi

P-01-10 The comparison between children with Attention Deficit Hyperactivity Disorder with their parents in integrated visual and auditory test results

R. Rostami, Iran
M. Bidadian, J. Zarei

Scientific Programme – Friday, 27 May 2011

P-02 Guided Poster Tour

14.30–16.00 h Main Foyer

Co-morbidity: Children and adolescents I

Chairpersons: C. Freitag, Germany
B. Maughan, United Kingdom

P-02-01 Anxiety symptomatology in ADHD children – a comparison study between probands and their siblings
D. Segenreich, Brazil
R. Suwwan, J. Sergeant, P. Mattos, D. Fortes, J. Torres, L. Novo

P-02-02 The risk of overweight and obesity in boys with Attention Deficit Hyperactivity Disorder
T. Hanc, Poland
A. Slopian, T. Wolanczyk

P-02-03 Game addiction and ADHD in early elementary age children
S.-C. Kim, Republic of Korea
I.-W. Chung, S.-W. Park, H. Yoo, S.-C. Cho

P-02-04 Neuropsychological profiles in ADHD preschoolers: Relation between executive functions and language competences
M. G. Melegari, Italy
M. Innocenzi, A. Costa, L. Canzano, F. Baccarin, F. Martines, S. LaPietra, A. Marano

P-02-05 Does the clinical profile of children with Attention Deficit Hyperactivity Disorder with comorbid mood disorder differ from those without comorbid mood disorder?
P. Palaniappan, India
S. Seshadri, S. Srinath, S. Girimaji

P-02-06 Comorbid Attention Deficit Hyperactivity Disorder in a sample of Brazilian children with Attention Deficit Hyperactivity Disorders (ADHD)
S. M. M. Palma, Brazil
S. Rizzutti, L. F. Coelho, S. A. Oncalla, D. L. F. Barbosa, R. Barbosa, M. C. Miranda, O. F. A. Bueno, M. Muszkat

P-02-07 A clinical study of phenomenology and comorbidity of ADHD in Indian children
A. Vaithiyam, India
K. Devendran

P-02-08 The impact of culture on language and speech competence of children with ADHD

L. Zasyekina, Ukraine

P-02-09 Analysis of leiter-r profiles in comparing ADHD children with high functioning pervasive developmental disorder not otherwise specified in preschoolers
F. Manti, Italy
A. Fabrizi, F. Giovannone

P-02-10 Neurological soft signs in children with Attention Deficit Hyperactivity Disorder compared to Asperger syndrome
E. D'Agati, Italy
L. Casarelli, M. Pitzianti, A. Pasini

P-03 Guided Poster Tour

14.30–16.00 h Main Foyer

Co-morbidity: Children and adolescents II

Chairpersons: S. Walitza, Switzerland
F. Poustka, Germany

P-03-01 Pervasive developmental disorders (PDD) with Attention Deficit Hyperactivity Disorder (ADHD) and chronic multiple tic disorder (CMTD) in children and adolescents
I. Martsenkovsky, Ukraine

P-03-02 Family adversity risk factors for ADHD and associated disruptive behaviour disorders in Singapore
N. Lim-Ashworth, Singapore
Y. P. Ooi, C. G. Lim, D. S. Fung, R. P. Ang

P-03-03 ADHD and learning disabilities as factors of school unsuccess
I. Martsenkovska, Ukraine
I. Martsenkovsky, K. Svetlana

P-03-04 Attachment patterns in Attention Deficit Hyperactivity Disorder with and without Severe Mood Dysregulation: Preliminary results
C. Paloscia, Italy
C. Rosa, F. Manaresi, R. Alessandrelli, A. Marianecchi, A. Pasini

P-03-05	Bipolar disorder diagnostic among ADHD population use of child Bipolar Questionnaire (CBQ, Papolos, 2006) A.-L. Thoumy, France A. Gaiffas, M. P. Bouvard	P-04-02	The influence of ADHD phenotype on screening for Dyslexia A. Duguid, United Kingdom U. Müller
P-03-06	Attention Deficit Hyperactivity Disorder: Co morbidity and multimodal management of children attending community clinic in a patch of Midessex, UK P. Sahare, United Kingdom	P-04-03	ADHD in treatment seeking patients with substance use disorders: prevalence and usefulness of the Adult ADHD Self-Report Scale (ASRS) as a screener M. Konstenius, Sweden S. Wallhed, G. van de Glind, W. van den Brink, J. Franck
P-03-07	Verbal turns difficulties in 4-5 years old Saudi males with ADHD W. Al-Dakrouy, Saudi Arabia N. Hewlett, J. Watson, H. Gardner	P-04-04	The possible role of childhood ADHD in the development of adult heroin dependence C. Barta, Hungary A. Szilagyi, K. Boor, A. Szekely, Z. Demetrovics, J. Csorba, M. Sasvari-Szekely
P-03-08	Do ADHD children with a CBCL-Dysregulation profile have specific treatment outcomes, clinical and cognitive features? H. Peyre, France M. Speranza, D. Purper-Ouakil	P-04-05	Association of atomoxetine treatment with substance use and abuse in a drug using population with Attention Deficit Hyperactivity Disorder I. Petrakis, Greece G. Dermatis
P-03-09	Reader profiles in ADHD subtypes in 7 – 10 years old children in Malaga (Spain) M.-J. Diaz, Spain M.-J. Diaz, A. Lora-Espinosa, M. Lopez-Zamora, J. L. Luque-Vilaseca, N. Mendoza	P-04-06	ADHD and substance abuse: Could sensation seeking be a moderating factor? A. Burke, South Africa
P-03-10	Gender differences in internalized and externalized problems of children with ADHD I. Jerkovic, Serbia R. Damjanovic, Š. Golubovic	P-04-07	Teenage pregnancy, ADHD and co-existing substance misuse disorders; a review and exploration of 2 case studies D. Judge, United Kingdom S. Gracias
P-04	Guided Poster Tour	P-04-08	Internet addiction in male adolescents with untreated ADHD – first results of an out-patient diagnostic and treatment program in Berlin O. Bilke-Hentsch, Switzerland T. Hellenschmidt
14.30 – 16.00 h	Main Foyer	P-04-09	The impact of childhood ADHD on the severity of addiction, and on subsequent SUD treatment efficacy M. Kapitány-Fövény, Hungary Z. Demetrovics
Co-morbidity: Adults I	Chairpersons: G. van de Glind, The Netherlands W. van den Brink, The Netherlands		
P-04-01	Adult Attention Deficit Hyperactivity Disorder and obesity: A case-control study M. F. Docet, Spain A. Larrañaga, J. L. Fernandez Sastre, L. F. Pérez Méndez, R. V. García-Mayor		

Scientific Programme – Friday, 27 May 2011

P-04-10	Substance use disorder with comorbid Attention Deficit Hyperactivity Disorder Y.-A. Kaufmann, Switzerland J.-G. Bavarel, R. Khan, D. Zullino	P-05	Guided Poster Tour
P-04-11	Screening for ADHD among patients with SUD in the MMT Programme in Malaysia: A new avenue for SUD treatment H. Peters, Malaysia	14.30 – 16.00 h	Main Foyer
P-04-12	ADHD and addictions: Clinical characteristics and outcome in a residential treatment population T. Schneekloth, USA A. Rai, D. Hall-Flavin, V. Karpyak, L. Loukianova, J. Geske, J. Biernacka, M. Frye, D. Mrazek	Epidemiology: Children and adolescents I Chairpersons: M. Romanos, Germany M. Schlander, Germany	
P-04-13	Association between Attention Deficit Hyperactivity Disorder(ADHD) and craving among patients with Alcohol Use Disorders (AUD) A. Seitz, Switzerland P. Allemann, H. Klingemann, P. Eggli, Y. Burren, M. Wapp, K. Schläfli, S. Stutz, C. Buri, F. Moggi, I. Icasa	P-05-01	ADHD is associated to atopic eczema M. Romanos, Germany A. Buske-Kirschbaum, V. Rössner, S. Weidinger, J. Schmitt
P-04-14	Validation research of modified Lesch Alcoholic Typology including group of alcohol addicted patients with comorbid ADHD spectrum disorders S. Syrek, Sweden M. Sznabowicz	P-05-02	Accidents and Attention Deficit Hyperactivity Disorder in 6 – 14-year-old schoolchildren in Andalusia (Spain) A. Lora-Espinosa, Spain M. J. Diaz-Aguilar, J. Murcia, M. Montes, N. Martinez, M. I. Vazquez, A. Prosper, J. Barea, R. Hergueta, R. Jimenez, N. Mendoza
P-04-15	Traits of attention deficit disorders in typologies of alcohol addiction S. Syrek, Sweden L. Lapiczak, P. Potapinski, M. Sznabowicz	P-05-03	The impact of coexisting mental health conditions on the cost of health service provision for children and adolescents with and without Attention Deficit Hyperactivity Disorder (ADHD) in Germany M. Schlander, Germany O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer, W. Scheller
P-04-16	Impulsiveness and TCI traits in amphetamine and multisubstance depended patients – preliminary report M. Sznabowicz, Poland S. Syrek, J. Iskra, B. Karakiewicz	P-05-04	ADHD co-morbidity of child and juvenile sex offenders C. Cangin, USA P. Taylor
		P-05-05	Measures of inhibition support the prediction of early academic skills J. Merkt, Germany C. Gawrilow
		P-05-06	Children suspected to have ADHD suffer from family dysfunction instead either as sole diagnosis or as a co-morbidity A. Schmidt, Brazil E. Paiva Ayres, C. Brandalise Antoniazzi, C. Hilgert, F. Mugnol, F. Driemeier, F. Dattora, D. Pianetti, J. Fries

Scientific Programme – Friday, 27 May 2011

P-05-07	Early school enrolment and increased rate of ADHD outpatient service use- risk of undue ADHD diagnosis? Ö. Albayrak, Germany S. Beck, J. Hebebrand	P-06-03	Incidence and prevalence of adult Attention Deficit Hyperactivity Disorder in a large managed care organization in Southern California A. Kawatkar, USA T. K. Knight, V. Sikirica, P. Hodgkins, R. A. Moss, M. H. Erder, M. B. Nichol
P-05-08	Family healthcare and Attention Deficit Hyperactivity Disorder in France C. Gétin, France K. Keddad, M. Lecendreux	P-06-04	Attention Deficit Hyperactivity Disorder screening as three-way direction and interaction for the prevention of disorder A. Lakic, Serbia A. Kesic
P-05-09	ADHD in Tunisia: Clinical and management particularities S. Othman, Tunisia Z. S. Abbes, S. Halayem, F. Charfi, A. Belhadj, A. Bouden, M. Halayem	P-06-05	Prevalence of Attention Deficit Hyperactive Disorder (ADHD) in school children in Al-Qaser district Jordan O. Nafi, Jordan
P-05-10	Preschoolers with ADHD: Clinical presentation, demographic data, frequency of methylphenidate treatment and treatment response K. Borregaard, Denmark E. M. Olsen, T. Houmann, J. Dyrborg, C. Anhøj	P-06-06	Characteristics of ADHD subtypes in a group of children from canton Ticino G. P. Ramelli, Switzerland G. P. Ramelli
P-05-11	Epidemiological study on symptoms of attention deficit and hyperactivity in a sample of 847 Brazilian children of public schools, according to the DSM-IV and teachers' ratings S. Antoniuk, Brazil s. antoniuk, I. Bruck, M. C. Bromberg, E. Maluf, D. Carvalho, M. Richartz, M. Cat	P-06-07	Prevalence of ADHD in Lebanese school-aged population S. Richa, Lebanon
P-06 Guided Poster Tour		P-06-08	Early hospital morbidity in children treated for Attention Deficit Disorder in Western Australia: A population data linkage study D. Silva, Australia L. Colvin, F. Stanley, C. Bower
14.30 – 16.00 h	Main Foyer	P-06-09	Prevalence of ADHD subtypes worldwide M. Skounti, Greece L. Betts
Epidemiology: Children and adolescents II Chairpersons: L. A. Rohde, Brazil R. Anney, Ireland		P-06-10	Prevalence change trend of Attention Deficit Hyperactivity Disorder in Taiwan M.-Y. Wang, Taiwan
P-06-01	The prevalence of ADHD in children at basque country J. M. Garcia Cruz, Spain X. Txakartegi, A. Bilbao		
P-06-02	A 3 year longitudinal ADHD and ODD prevalence research in a Turkish sample B. Kabukcu Basay, Turkey E. S. Ercan, L. A. Rohde, R. Kandulu, E. Uslu, C. Aydin		

Scientific Programme – Friday, 27 May 2011

P-07 Guided Poster Tour

14.30–16.00 h Main Foyer

Epidemiology: Adults I

Chairpersons: J. Haavik, Norway
M. Muenke, USA

- P-07-01 ADHD prevalence in a sample of obese women**
B. P. Nazar, Brazil
C. Moreira de Sousa Pinna, R. Suwwan, J. A. Sergeant, P. Mattos
- P-07-02 Profile of psychiatric comorbidity, health history and socio-demographic characteristics in a sample of Puerto Rican prison inmates with ADHD symptomatology**
M. Velez Pastrana, Puerto Rico
R. Gonzalez, E. Lopez Toro, L. Estrada Rivera, C. Albizu Garcia
- P-07-03 ADHD: A new diagnosis in elderly populations**
A. Rojo Pantoja, Spain
J. L. Fernandez Sastre, E. Fernandez
- P-07-04 ADHD and mild cerebral dysfunction in adult psychosomatic patients**
M. H. Warnke, Germany
M. Linden
- P-07-05 Do prison inmates with ADHD differ from psychiatric outpatients with ADHD and healthy controls in ADHD symptom profiles and executive functions?**
Y. Ginsberg, Sweden
T. Hirvikoski, N. Lindefors
- P-07-06 ADHD prevalence in medical students at Ross University School of Medicine**
S. Davenaranand, USA
R. Gee, M. M. Cuffy, D. Sharma, J. Douglas, J. Boleski
- P-07-07 High prevalence of adult Attention Deficit Hyperactivity Disorder in Spain: Population-based study**
M. F. Docet, Spain
J. L. Fernandez Sastre, R. V. Garcia-Mayor
- P-07-08 ADHD in a forensic facility**
S. Gangadharan, Singapore

P-07-09

The prevalence of Attention Deficit Hyperactivity Disorder in older adults in the Netherlands

M. Michielsen, The Netherlands
E. Semeijn, H. Comijs, A. Beekman, D. Deeg, S. Kooij

P-07-10

Persistence of ADHD symptoms into seniority – related with social functioning

F. Philipp-Wiegmann, Germany
I. Rauber, A. Schmitt, M. Bauer, W. Retz, M. Rösler

P-07-11

Why blindness adolescence doesn't report ADHD problems?

H. Saberi, Iran

P-07-12

Relationships between sleep, seasonal affective symptoms, health, and ADHD: The ASES study

D. Bijlenga, The Netherlands
K. B. van der Heijden, M. Breuk, M. E. H. Lie, E. J. W. van Someren, H. J. T. Swaab-Barneveld, J. J. Sandra Kooij

P-08 Guided Poster Tour

14.30–16.00 h Main Foyer

Genetics studies

Chairpersons: K.-P. Lesch, Germany
T. Renner, Germany

P-08-01

The accumulation of several recessive markers by psychic desadaptation

O. Drevitska, Ukraine

P-08-02

Methylenetetrahydrofolate reductase gene polymorphisms in children with Attention Deficit Hyperactivity Disorder

C. Gökçen, Turkey
N. Kocak, A. Pekgor

P-08-03

A neuropeptide S receptor gene variant and adverse life events are associated with increased aggressiveness and inattention in a population representative sample of adolescents

J. Harro, Estonia
E. Kiive, K.-P. Lesch, J. Mäestu, T. Veidebaum, A. Reif

P-08-04	Effect of the serotonin transporter gene promoter polymorphism on inattentive symptoms in a population representative sample of adolescents E. Kiive, Estonia D. Eensoo, H.-M. Loit, J. Harro	P-08-11	Why do ADHD symptoms and reading disability co-occur? A longitudinal genetic study of more than 12000 twins C. Greven, United Kingdom F. Rijdsdijk, P. Asherson, R. Plomin		
P-08-05	Effect of ADRA2A and BDNF gene – gene interaction on the continuous performance test phenotype H.-W. Kim, Republic of Korea S.-C. Cho, B.-N. Kim Kim, J.-W. Kim, S. Y. Kim	P-08-12	Association study on NPY and NPY1R and body weight in ADHD T. Renner, Germany S. Baranski, T. Seip, T. Nguyen, M. Romanos, J. Heinrich, C. Tiesler, M. Gerlach, A. Warnke		
P-08-06	Association between BAIAP2 gene polymorphisms and Attention Deficit Hyperactivity Disorder in Han Chinese Subjects Z. Li, People’s Republic of China Y. Wang, Q. Qian, Y. Chen, N. Ji, L. Liu, H. Li, L. Yang	P-08-13	COMT x DRD4 epistasis impacts neural and behavioral response control in adult patients with Attention Deficit Hyperactivity Disorder (ADHD) and healthy controls S. Heinzl, Germany C. G. Bähne, M. Heine, A. Boreatti-Hümmer, C. P. Jacob, T. J. Renner, A. Reif, K.-P. Lesch, A. J. Fallgatter, A.-C. Ehls, T. Dresler		
P-08-07	Shared genetic influences on parent, teacher and self-ratings of ADHD symptoms: A twin study in early adolescence A. Merwood, United Kingdom C. Greven, T. Price, G. McLoughlin, J. Kuntsi, H. Larsson, P. Asherson	P-08-14	Family based genetic study of child ADHD and DRD2 / ANKK1 gene in a french sample M. Wohl, France C. Boni, D. Purper-Ouakil, S. Bahabori		
P-08-08	Male biasness of Attention Deficit Hyperactivity Disorder: Importance of dopaminergic gene variants and environment K. Mukhopadhyay, India M. Das, N. Bhaduri, A. Das Bhowmik, K. Sarkar, P. Ghosh, K. Sarkar, A. Ray, A. Chatterjee, S. Sinha	<table><tr><td>P-09</td><td>Guided Poster Tour</td></tr></table>		P-09	Guided Poster Tour
P-09	Guided Poster Tour				
P-08-09	Preliminary results show no distinct pattern of 5,10-methylenetetrahydrofolate reductase gene polymorphisms in Attention Deficit and Hyperactivity Disorder A. Tufekci, Turkey Y. Taneli, E. Kirhan, M. Dirican	14.30 – 16.00 h Main Foyer Etiopathogenesis Chairpersons: E. Grünblatt, Switzerland S.-C. Cho, Republic of Korea			
P-08-10	Diras2: Candidate gene for Attention Deficit Hyperactivity Disorder L. Weißflog, Germany T. Nguyen, C. Jacob, M. Romanos, C. Freitag, H. Schäfer, B. Cormand, J. Haavik, B. Franke, K.-P. Lesch, A. Reif	P-09-02	Alexithymia and attachment styles in parents of Children with Attention Deficit Hyperactivity Disorder C. Paloscia, Italy C. Rosa, F. Manaresi, R. Guerini, A. Pasini		
		P-09-03	Hyper reaction of the defense administration in the human brain: ADHD – Attention Deficit Disorder as a consequence of genetics and imprinting K. Dietrich, Germany		
		P-09-04	The importance of HPA axis as an etiological factor for ADHD N. Vuksanovic, Germany M. Bidlingmaier, D. Rujescu, K. Zeber, J. Borns, C. Kern, K. H. Brisch		

Scientific Programme – Friday, 27 May 2011

P-09-05	ADHD symptoms in adults are related to the biological clock H. Caci, France V. Oliveri, K. Dollet	P-10-03	ADHD and psychosocial stressors. The DTI findings about myelinization process among these patients I. Souza, Brazil R. Dominguez, P. Mattos, E. Curty
P-09-06	Environmental exposure to bisphenol A and phthalates in relation to childhood attention, behavior, learning, and intelligence, as well as the diagnosis of Attention Deficit Hyperactivity Disorder S.-C. Cho, Republic of Korea S.-B. Hong, J.-W. Kim, E.-J. Park, M.-S. Shin, B.-N. Kim, H.-J. Yoo, I.-H. Cho, S.-Y. Bhang, Y.-C. Hong	P-10-04	Examining volumetric differences in the PFC of a pediatric spanish sample with ADHD and normal controls using a highly-calibrated manual tracing protocol E. Dierenfeld, Canada M. A. Garcia-Barrera, J. Hatter, R. Caulfield, L. Shayegi Nick, J. Wilson, N. Trujillo-Orrego, E. Perez-Hernandez
P-09-07	The therapeutic pet as a supporting form of intervention in child "pseudo-behavior" Attention Deficit and Hyperactivity Disorder (ADHD) E. Furlani, Greece P. Gouveris, E. Michael, T. Syriopoulou, E. Karachanidi, K. Straka, I. Maggana, A. Hristopoulou	P-10-05	fMRI study with MSIT: Difference in neural activity between school age children with Attention Deficit Hyperactivity Disorder compared with healthy school age controls A. Rizzoli-Cordoba, Mexico N. Gonzalez, S. Liendo, E. Barragan
P-09-08	Ferritin and hyperactivity symptoms in a large clinical sample P. Oner, Turkey O. Oner, E. Cop, K. Munir	P-10-06	Magnetic Resonance spectroscopy study in cerebellar vermis difference between school age children with Attention Deficit Hyperactivity Disorder compared with healthy school age controls E. Barragan, Mexico N. Gonzalez, S. Garza, J. Hernandez, F. Eduardo
P-10	Guided Poster Tour		
14.30 – 16.00 h		Main Foyer	
Imaging studies: Children and adolescents Chairpersons: K. Konrad, Germany K. Rubia, United Kingdom		P-10-07	Difference in the cerebellar vermis volume between school age children with Attention Deficit Hyperactivity Disorder compared with healthy school age controls N. Gonzalez, Mexico S. Liendo, J. L. Madrigal, J. Hernandez, E. Barragan, S. Garza, A. Rizzoli
P-10-01	Single-dose Methylphenidate normalized resting-state brain dysfunction in boys with Attention Deficit Hyperactivity Disorder: A functional MRI study L. An, People's Republic of China X. Cao, Y. Zang, Q. Cao, L. Sun, J. Ren, Z. Qing, Y. Wang	P-10-08	The impact of reward on episodic memory formation in attention-deficit/hyperactivity disorder U. Malecki, Germany E. Duezel, H. Hinrichs, C. Rehe, S. Tyll, T. Noesselt, H.-H. Flechtner, K. Krauel
P-10-02	Default mode network abnormality in medication-naïve ADHD boys : Resting-state fMRI study J. Choi, Republic of Korea B. Jeong		

P-10-09	Voxel-morphometry and neuropsychological analysis in a sample of ADHD children C. B. de Mello, Brazil A. Jackowski, R. G. Nogueira, S. Rizzutti, O. F. A. Bueno, M. Muszkat	P-11	Guided Poster Tour
		14.30–16.00 h	Main Foyer
P-10-10	Differences in neurometabolites measurements in the cingulus of scholar patients with and without Attention Deficit Hyperactivity Disorder by proton MR spectroscopy M. Pizarro, Mexico A. Rizzoli, E. Barragan, E. Flores, A. Partida, S. Garza	Imaging studies: Adults Chairpersons: L. Tebartz van Elst, Germany A. Konrad, Germany	
		P-11-01	Altered integrity of cerebellar white matter in adult patients diagnosed with ADHD P. Goll, Germany S. Maier, E. Perlov, S. Klöppel, D. Endres, A. Philipsen, L. Tebartz van Elst
P-10-11	Functional connectivity patterns differences in drug naive children with ADHD during working memory-related processes H. Slama, Belgium P. Peigneux, A. Mary, M. Kavec, S. Linotte, D. Balériaux, T. Metens, I. Massat	P-11-02	Cerebellar volume deficits in adult ADHD S. Maier, Germany E. Dieter, E. Perlov, S. Klöppel, A. Philipsen, L. Tebartz van Elst
		P-11-03	A proton MRS study of the basal ganglia, dorsolateral prefrontal cortex and parietal lobe in adults with Attention Deficit Hyperactivity Disorder S. Maltezos, United Kingdom S. Coghlan, T. Lavender, R. O’Gorman, C. Skirrow, K. Xenitidis, P. Mark, D. Spain, P. Asherson, D. Murphy
P-10-12	Adolescent brain have different activation pattern against different reward condition J. Son, Republic of Korea W.-H. Choi, Y.-R. Kim, S. Y. Park	P-11-04	Amygdala subdivision connectivity in adult patients with ADHD M. M. Plichta, Germany S. Esther, D. Mier, C. Sauer, O. Grimm, A. B. M. Gerdes, D. Sabljic, B. Alm, P. Kirsch
		P-11-05	Functional brain imaging of delay aversion in adult ADHD G. Wilbertz, Germany A. Trüg, J. Blechert, L. Tebartz van Elst, E. Sonuga-Barke
P-10-13	Is the clinical, cognitive and brain biochemical expression of Attention Deficit Hyperactivity Disorder different in children born late preterm versus children born at term? L. Ben Amor, Canada S. Chantal, A. Bairam	P-11-06	No difference of dopamine transporter availability in adults with Attention Deficit Hyperactivity Disorder C.-B. Yeh, Taiwan M.-C. Lo, C.-J. Chang, K.-H. Ma, W.-S. Huang
		P-11-07	3D brain SPECT imaging of ADHD presenting as Borderline personality disorder: A case report H. Schneider, Canada M. McLean, M. Freeman, J. Thornton, M. van Lierop, R. Tarzwell
P-10-14	Basal ganglia differences between good or bad responders to metilphenidate in ADHD children. A VBM and a ROI-based study A. Moreno, Spain L. Duñó, E. Hoekzema, M. Picado, L. M. Martin, O. Vilarroya		

Scientific Programme – Friday, 27 May 2011

P-11-08 Correlation of inattention and impulsivity with regional brain volume in adult patients with ADHD

A. Konrad, Germany
T. Dielentheis, G. Vucurevic, M. Huss

P-11-09 Increased Creatin, Cholin and Glutamat+ Glutamin (Glx) concentrations in hyperactive patients with ADHD

D. Endres, Germany
E. Perlov, S. Maier, P. Goll, A. Philipsen, L. Tebartz van Elst

P-12 Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Pathophysiology: Children and adolescents I

Chairpersons: A. Conzelmann, Germany
A.-C. Ehls, Germany

P-12-01 Psychomotor profile of children with Attention Deficit Hyperactivity Disorder combined type

J. Goulardins, Brazil
E. Barbante Casella, J. Marques, M. Periotto, S. Pacheco, T. Freire, U. Reed

P-12-02 The relation between cognitive empathy, beliefs about aggression and proactive aggression in children and adolescents with disruptive behaviour disorders

L. Su, Singapore
Y. P. Ooi, R. P. Ang, S.-J. Weng, J. C. Liu, A. Raine, D. S. Fung

P-12-03 Motivation and interference control in children and adolescents with Attention Deficit Hyperactivity Disorder: A research plan

I. Ma, The Netherlands
K. H. Putnam, A. Scheres

P-12-04 The differential aspects of cognitive profiles of students with Attention Deficit Hyperactivity Disorder

À. Mies, Spain
A. Fornieles, E. Jurado, M. Quintana

P-12-05 Children with ADHD show the same pattern of impairment in working and long-term memory

S. Rhodes, United Kingdom
J. Park, S. Seth, D. Coghill

P-12-06 Higher order theory of mind in preschool boys at risk of ADHD

M. Wozniak-Prus, Poland
E. Pisula

P-12-07 Sensory processing profile in children with Attention Deficit Hyperactivity

V. Tiemi Shimizu, Brazil
M. Carolina Miranda

P-12-08 Working memory deficits in Attention Deficit Hyperactivity Disorder

K. Knight, USA
A. Scheres

P-12-09 Working memory performance of children with ADHD versus clinical controls

J. Lemiere, Belgium
E. Rymen, J. Dillen, M. Danckaerts

P-12-10 Analysis of affective disorder in children with Attention Deficit Hyperactivity Disorder–ADHD by Rorschach Test

R. Figaro, Brazil
C. A. Araujo, M. Muszkat, M. C. Miranda, S. Rizzutti, S. M. M. Palma, L. F. Coelho, F. Dias, O. F. A. Bueno

P-12-11 Clinical and neuropsychological profile in a sample of children with Attention Deficit Hyperactivity Disorders (ADHD)

S. Rizzutti, Brazil
L. F. Coelho, S. M. Mota Palma, R. Figaro, D. Barbosa, F. Dias, M. Miranda, O. F. A. Bueno, M. Muszkat

P-13 Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Pathophysiology: Children and adolescents II

Chairpersons: I. Wolf, Germany
V. Jucksch, Germany

P-13-01 Symptoms of Attention Deficit Hyperactivity Disorder in children: Differential effects on response inhibition?

L. Sorensen, Norway
K. J. Plessen, S. Adolphsottir, E. Wehling, A. J. Lundervold

P-13-02 Selected executive functions in ADHD diagnosed children

M. Dabkowska, Poland
W. Chytra-Gedek, M. Mitros

- P-13-03** **Comparison of neuropsychological functions in subtypes of children with ADHD**
M.-S. Shin, Republic of Korea
J.-K. Ahn
- P-13-04** **Visuospatial abilities in children with and without Attention Deficit Hyperactivity Disorder**
H. Alizadeh, Iran
S. Dehghan Manshadi
- P-13-05** **A comparison of children's attention and cognitive function across noise conditions – a randomized controlled study**
S.-Y. Bhang, Republic of Korea
J. Lee, C. Lee, J. Yoon, C. Shim, J. Sung
- P-13-06** **Neuropsychological functioning in clinical subtypes of drug naïve girls with Attention Deficit Hyperactivity Disorder**
C. Paloscia, Italy
R. Alessandrelli, C. Rosa, A. Pasini
- P-13-07** **Attentional impairment in children with Attention Deficit Hyperactivity Disorder**
Z. S. Abbes, Tunisia
A. Bouden, M.-C. Bourdel, K. Tabbane, I. Amado
- P-13-08** **Attention supporting conditions enhance recognition of emotional facial expressions (REFE) in children with ADHD**
R. Geva, Israel
D. Tamari
- P-13-09** **Investigation of the relationship between executive functions and theory of mind in Attention Deficit Hyperactivity Disorder**
H. Slama, Belgium
P. Mousty, P. Peigneux, I. Massat, A. Mary
- P-13-10** **Fluency strategies in ADHD: Language-based compensatory behavior in task solving**
A. Takács, Hungary
A. Kóbor, Z. Tárnok, V. Csépe
- P-13-11** **Is dual task coordination available in ADHD?**
K. Inasaridze, Georgian
V. Bzhalava, L. Chikvaidze

- P-13-12** **A qualitative study on the effects of silently-whispered and / or softly-pronounced vs loud and serious verbal instructions during occupational therapy sessions on an Iranian sample of children with Attention Deficit Hyperactivity Disorder**
S. Nakhai, Iran
F. Behnia

P-14

Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Pathophysiology: Adults I

Chairpersons: A. Fallgatter, Germany
M. Colla, Germany

- P-14-01** **Self-report of executive function deficits and self-concept in adults with ADHD**
R. Drechsler, Switzerland
P. Rizzo, H.-C. Steinhausen
- P-14-02** **Utility of the INECO Frontal Screening (IFS) for the detection of executive dysfunction in patients with adult ADHD and bipolar disorder**
B. Sandra, Argentina
E. Gleichgerricht, H. Urquina, A. Lischinsky, M. Roca, F. Manes, T. Torralva
- P-14-03** **Classification of ADHD and healthy control adults using event-related potentials and independent component analysis**
A. Müller, Switzerland
G. Candrian, J. D. Kropotov, G. M. Baschera, V. Arnstberg Grane, V. Ponomarev
- P-14-04** **Frequency and dental consequences of bruxism in adults with Attention Deficit Hyperactivity Disorder (ADHD)**
M. A. Silva, Brazil
L. M. D. Aguiar, E. F. O. Firsoff, C. M. Agra, M. Louza, G. F. Vieira
- P-14-05** **Neuropsychological assessment of executive functions and psychology profile in adult with ADHD**
B. Rubio, Spain
J. Bravo, S. Hernández, P. Gonzalez Perez

Scientific Programme – Friday, 27 May 2011

P-14-06	Performance in the game of dice task in adults with ADHD S. Matthies, Germany J. Svaldi, C. Nober, A. Philipsen	P-15-02	Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A case series demonstrating improved outcome when comorbid ADHD is treated with long-acting stimulant medication (LAS) G. Farrelly, Canada M. Zwiers
P-14-07	Emotion regulation by the use of mindfulness instruction in adult Attention Deficit Hyperactivity Disorder S. Matthies, Germany J. Svaldi, C. Sadohara, P. Borel, A. Philipsen	P-15-03	Aripiprazole in children and adolescents with conduct disorder: A single-center, open-label study E. S. Ercan, Turkey T. Uysal, E. Ercan, Ü. Akyol Ardiç
P-14-08	Adult ADHD and sensation seeking T.-L. Austin, South Africa	P-15-04	Does medication alleviate executive working memory deficits in children with ADHD? T. Schleepen, The Netherlands L. Jonkman
P-14-09	Attention Deficit Hyperactivity Disorder, reactive inhibition and emotional regulation in Puerto Rican adults T. Ilarraza, Puerto Rico M. Velez Pastrana, M. Rivera, J. Rodriguez	P-15-05	Methylphenidate-induced changes of cerebral frontal inhibitory functions in patients with Attention Deficit Hyperactivity Disorder T. H. Kim, Republic of Korea D.-H. Song, S.-J. Klm
P-14-10	Emotional reagibility and working memory performance—differential effects of emotional interference control in subjects with and without ADHD I. Marx, Germany G. Domes, C. Havenstein, C. Berger, L. Schulze, S. C. Herpertz	P-15-07	Five year follow up of psychosocial, sexual and academic outcome in children with Attention Deficit Hyperactivity Disorder (ADHD) under treatment R. Sagar, India K. Sinha Deb, M. Mehta
P-14-11	Neurocognitive deficiencies in adult ADHD; cognitive functions as marker and core deficit O. Pazvantoglu, Turkey A. Aker Alptekin, K. Karabekiroglu, G. Sarisoy, S. Akbas, S. Baykal, I. Zabun Korkmaz, E. Alkan Pazvantoglu, O. Boke, A. Rifat Sahin	P-15-08	Effectiveness of treatment on psychosocial adjustment and academic outcome in children with Attention Deficit Hyperactivity Disorder (ADHD): A six month follow-up study K. Sinha Deb, India R. Sagar, A. Mittal, M. Mehta
P-15	Guided Poster Tour		
14.30–16.00 h		Main Foyer	
Pharmacological treatment: Children and adolescents I			
Chairpersons: T. Banaschewski, Germany A. Ludolph, Germany			
P-15-01	Examining the efficacy of atomoxetine on measures of cognition, emotional function and anxiety in children and adolescents with ADHD – The ACTION study M. Kohn, Australia T. W. Tsang, D. F. Hermens, S. D. Clarke, C. R. Clark, C. Lamb, D. Efron, N. Cranswick, L. M. Williams	P-15-09	Evaluation of cardiovascular effects of atomoxetine treatment upon children with Attention Deficit Hyperactivity Disorder C. Gökçen, Turkey A. Sert, E. Aypar, D. Odabas

P-15-10	Effects of w3 Long-Chain Polyunsaturated Fatty Acids (LCPUFA) supplementation on information processing of ADHD children medicated with Methylphenidate D. Isenberg Bechar, Israel R. Geva, E. Granot, D. Margalit	P-16-04	Methylphenidate effect on neuro-cognitive test battery E. S. Ercan, Turkey E. Ercan, F. S. Durak
P-15-11	The efficacy of ultralow doses of S100 protein antibodies in complex treatment of children with ADHD associated with anxiety E. Sagutdinova, Russia N. Semenova, E. Prokopieva, E. Naboychenko, S. Blokhina	P-16-05	Possible interaction effect of dopaminergic and noradrenergic gene polymorphisms on methylphenidate response in a Korean ADHD sample S. B. Hong, Republic of Korea H.-J. Yoo, B.-N. Kim, M.-S. Shin, S.-C. Cho, J.-W. Kim
P-15-12	Treatment response heterogeneity in children with ADHD during treatment with modified-release methylphenidate in the observational OBSEER study M. Döpfner, Germany C. Hautmann, A. Rothenberger	P-16-06	Monoamine oxidase a gene is associated with methylphenidate response in ADHD children: Results in two independent samples L. Yang, People's Republic of China Y. Chen, L. Liu, H. Zhang, Y. Wang
P-16	Guided Poster Tour	P-16-07	Pharmacotherapy of Attention Deficit Hyperactivity Disorder in children with epilepsy A. Kesic, Serbia A. Lakic, V. Milovanovic, P. Ignjatovic
14.30 – 16.00 h	Main Foyer	P-16-08	Treatment adherence of osmotic release oral system-methylphenidate in children and Adolescents with Attention Deficit Hyperactivity Disorder H. Yoo, Republic of Korea B. Kim, A. Y. Son, C. Suh
Pharmacological treatment: Children and adolescents II Chairpersons: H.-C. Steinhausen, Switzerland A. Kutzelnigg, Austria			
P-16-01	A single-center, single-blind, randomized, oral dose cross-over study in prepuberal boys with ADHD to investigate efficacy and bioequivalence of two modified release Methylphenidate formulations C. Fleischaker, Germany K. Hennighausen, K. Schneider-Momm, E. Schulz	P-16-09	Alterations of oral language in the Attention Deficit Hyperactivity Disorder and correlation with stimulant treatment M. Periotto, Brazil E. Barbante Casella, S. Pacheco, S. Branco, U. Reed
P-16-02	Side effects in adhd patients treated with methylphenidate: A comparison between different formulations M. Pinto, Portugal C. Cordovil, C. Amado	P-16-10	A re-examination of acute tolerance, Tachyphylaxis and Hysteresis Loop in the Pharmacokinetics and Pharmacodynamics of immediate release methylphenidate in individuals with ADHD M. Cavangh, Canada M. Denis, D. Quinn
P-16-03	Effect of increasing doses of methylphenidate as a function of free salivary cortisol and comorbid anxiety in children with ADHD P. Robaey, Canada R. Menneh, P. Hastings, I. Fortier, L. Simard		

Scientific Programme – Friday, 27 May 2011

P-16-11 Effects of methylphenidate treatment on ROS formation in the blood of children with ADHD

P. Heiser, Germany
O. Sommer, A. Hoinkes, M. Röttinger, U. Hopt, A. Schmidt, E. Schulz, K. Hen-nighausen, H.-W. Clement

P-16-12 Osmotic-controlled release oral delivery system Methylphenidate treatment reduces parental stress in children and adolescents with Attention Deficit Hyperactivity Disorder in Korea

H. Yoo, Republic of Korea
J. M. Ahn, B. Kim, Y. J. Park

P-17

Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Pharmacological treatment: Adults I

Chairpersons: M. Rösler, Germany
C. Jacob, Germany

P-17-01 Usage trends of ADHD medication by bipolar patients with attentional deficits

I. Szpindel, Canada
R. McIntyre

P-17-02 Systematic parametric assessment of attentional dysfunction in medicated adult patients with attention-deficit hyperactivity disorder

W. Schwarzkopf, Germany
K. Hennig-Fast, U. Müller, T. Frodl, H. Müller, R. Engel, M. Riedel, H.-J. Möller, K. Finke

P-17-03 Long acting Methylphenidate improves cortical dysinhibition in adults with ADHD: A study with paired pulse Transcranial Magnetic Stimulation

M. Schneider, The Netherlands
W. Retz, G. Gougleris, W. Verhoeven, J. Tulen, M. Rösler

P-17-04 Mood stabilization protocol mitigates risk in high-risk ADHD

A. Ocana, Canada
R. Rivers

P-17-05 A randomised, double-blind cross-over, single-centre study to evaluate patient and physician reported outcomes on Concerta-Oros-Methylphenidate vs. the Generic Novo-Methylphenidate ER-C

A. Fallu, Canada
F. Daboux

P-17-06 Comparative effects of Methylphenidate and Atomoxetine on AQT processing speed in ADHD Adults: Preliminary findings

N. P. Nielsen, Denmark
E. H. Wiig

P-17-07 The positive impact of methylphenidate in a sample of patients with Irritable Bowel Syndrome

T. Freire Barbosa, Brazil
E. Barbante Casella

P-17-08 Driving performance of patients with Attention Deficit Hyperactivity Disorder (ADHD) after treatment with methylphenidate (MPH): Systematic review of randomized controlled trials

M. A. Gobbo, Brazil
M. Louza

P-17-09 Does Biphentin have a significant clinical impact on attentional networks in individuals with ADHD?

K. Saliba, Canada
U. Jain, R. Tannock

P-17-10 Predictive factors for more than 3 years duration of central stimulant treatment in adult ADHD: A retrospective, naturalistic study

T. Torgersen, Norway
B. Gjervan, H. M. Nordahl, K. Rasmussen

P-17-11 Relapse of comorbid substance use disorder during central stimulant treatment in severe adult ADHD

T. Torgersen, Norway
B. Gjervan, K. Rasmussen, H. M. Nordahl

P-17-12 Driving risk in adult ADHD patients

U. Jain, Canada
K. Saliba, R. Yoon

P-18 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Pharmacological treatment: Adults II

Chairpersons: R. W. Dittmann, Germany
A. Reif, Germany

P-18-01 Psychopharmacological treatment of ADHD patients older than 50 years – a pilot study

M. B. Lensing, Norway
P. Zeiner, S. Opjordsmoen

P-18-02 A pilot study on the effects of nicotine on attention and concentration in students with adult ADHD symptomatology

S. Sayce, South Africa
A. Burke

P-18-03 Maintenance of efficacy of lisdexamfetamine dimesylate in adults with Attention Deficit Hyperactivity Disorder: Randomized withdrawal design

M. Gasior, USA
M. Brams, R. Weisler, R. Findling, M. Hamdani, M. C. Ferreira-Cornwell

P-18-04 Long duration of efficacy of lisdexamfetamine dimesylate, the first prodrug for Attention Deficit Hyperactivity Disorder

M. Gasior, USA
S. Wigal, T. Wigal, J. Gao, C. Richards

P-18-05 Metadoxine – a novel non-stimulant extended-release drug for treating adhd

I. Manor, Israel
Y. Daniely, D. Meggido, R. Yamin, A. Weizman

P-18-06 The effect of OROS methylphenidate and long-acting amphetamine salts on cognitive tasks in adults with Attention Deficit Hyperactivity Disorder: An open trial with blind placebo control comparison

T. Simon, Canada
M. Bilodeau, M. Beauchamp, R. Elie, P. Lespérance, S. Dubreucq, J.-P. Dorée, S. V. Tourjman

P-18-07 Pharmaceutical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults – an overview of available studies and the medical situation in Germany based on a health technology assessment

D. Benkert, Germany
K.-H. Krause, J. Wasem, P. Aidsburger

P-18-08 Pharmacological treatment for ADHD in adults: The Italian reality

B. Plattner, Italy
E. Duregger, A. Conca

P-18-09 Functional impairments of adult ADHD patients with or without co-morbid generalized anxiety before and after treatment with stimulants or non-stimulants: A comparative naturalistic study

S. Mousa, Canada
A. Gabriel

P-18-10 Individualized dosing with OROS® Methylphenidate to optimize treatment in adults with Attention Deficit Hyperactivity Disorder

B. Schaeuble, Germany
H. L. Starr, R. B. Armstrong, Y.-W. Ma, S. Ascher

P-18-11 Oros methylphenidate and patient-reported work-related outcomes in adults with Attention Deficit Hyperactivity Disorder

B. Schaeuble, Germany
S. Ascher, Y.-W. Ma, H. L. Starr

P-19 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Non pharmacological treatment: Children and adolescents I

Chairpersons: T. Jans, Germany
F. Zepf, Germany

P-19-01 Neurofeedback and standard pharmacological intervention in the improvement of Attention Deficit Hyperactivity Disorder symptomatology: Preliminary findings

V. Meisel, Spain
G. García-Banda, E. Cardo, M. Servera, P. Aggensteiner, T. Pérez, J. Picardo, I. Moreno

Scientific Programme – Friday, 27 May 2011

- | | |
|--|--|
| <p>P-19-02 Determining the effectiveness of reality therapy on reducing depression amongst mothers with children afflicted with Attention Deficit Hyperactivity Disorder
M. Darini, Iran
P. Azizi Khereshki, H. Davoodi, D. Darini</p> | <p>P-19-10 Treatment of ADHD in affected mothers and children—a randomized controlled multicentre trial: Patient enrolment and basic characteristics of the study sample
T. Jans, Germany
C. Jacob, K. Hennighausen, E. Graf, M. Rösler, S. Haenig, E. Sobanski, L. Poustka, M. Colla, R. Burghardt, A. Philipsen</p> |
| <p>P-19-03 Effect of music training and movement on reducing the symptoms of Attention Deficit Hyperactivity Disorder
M. Esteki, Iran
Z. Atashkar</p> | <p>P-19-11 A comparative study of effectiveness of neurofeedback and ritalin on improving conduct problems and hyperactivity of connors' index
M. Jadidi, Iran
E. Foroozandeh, M. M. Shamsaee, H. R. Nikkhah</p> |
| <p>P-19-04 Changes in omega 3/6 fatty acid plasma profiles in a randomized placebo-controlled study in children and adolescents with ADHD
M. Johnson, Sweden
J.-E. Månsson, S. Östlund, G. Fransson</p> | <p>P-19-12 The influence of yoga on the attention deficit and lateral dominance discoordination of children with Attention Deficit Hyperactivity Disorder (ADHD)
L. Azhdehfar, Iran
P. Golkarian</p> |
| <p>P-19-05 Empowerment and Insight Center for students with learning disabilities and ADHD
O. Tykochinsky, Israel
A. Frishman Shetrit</p> | <p>P-19-13 Children with ADHD attended outpatient clinic and day care program: The impact of psychosocial intervention
A. Al Ansari, Bahrain</p> |
| <p>P-19-06 Creativity training effects upon concept map complexity of children with Attention Deficit Hyperactivity Disorder (ADHD): An experimental study
K. Alkahtani, Saudi Arabia</p> | <p>P-19-14 Effects of computer base of attention training on sustain attention performance in children with Attention Deficit Hyperactivity Disorder
S. Bakhshi, Iran
E. Pishyareh, F. Behnia, V. Nejati</p> |
| <p>P-19-07 Cognitive behavioral therapy in the treatment of children with Attention Deficit Hyperactivity Disorder
L. F. Coelho, Brazil
M. C. Miranda, D. L. F. Barbosa, S. Rizzutti, M. Muszkat, S. M. M. Palma, F. Rosangela, F. Dias, O. F. A. Bueno</p> | <p>P-19-15 What changes in preschoolers with ADHD symptoms after a 14 week parental intervention: Preliminary results
A. Azevado, Portugal
M. J. Seabra-Santos, M. F. Gaspar, T. Homem, S. Leitão</p> |
| <p>P-19-08 An experiential-based psychotherapeutic plan for Attention Deficit Hyperactivity Disorder in children
G. Cucu-Ciuhan, Romania</p> | |
| <p>P-19-09 InterActive: An approach of group-therapy for adolescents with AD(H)D
T. Krause, Germany</p> | |

P-20 Guided Poster Tour

14.30–16.00 h Main Foyer

Non pharmacological treatment: Children and adolescents II

Chairpersons: O. Tucha, The Netherlands
U. Strehl, Germany

P-20-01 Cognitive rehabilitation using Pay Attention! Program in children with ADHD
D. Barbosa, Brazil

P-20-02 The effectiveness of using Perceptual-Motor Practices on behavioral disorder among five to eight year old children with Attention Deficit Hyperactivity Disorder
F. Dehghan, Iran
E. Pishyareh, F. Behnia, N. Amiri, M. Safarkhani

P-20-03 Effects of combined treatment on turkish children diagnosed with Attention Deficit Hyperactivity Disorder: A 12-month follow up study
E. S. Ercan, Turkey
A. Kutlu, S. Durak, U. Akyol Ardic

P-20-04 Effects of tactile and vestibular stimulation in reducing the symptoms of Attention Deficit and Hyperactivity Disorder
M. Ghahramany, Iran
M. Estaki, H. Ashayari, M. Ghahramani

P-20-06 A study of combined treatments in cognitive and behavioral symptoms of children with ADHD
M. Miranda, Brazil
M. Muszkat, S. Rizzutti, L. F. Coelho, D. Barbosa, O. Bueno

P-20-07 Effectiveness of guided parental self-help for parents of children with ADHD: An interim report on the study sample

L. Mokros, Germany
N. Benien, M. Döpfner

P-20-08 Effects of teaching problem solving skills on attention and social skills of students with ADHD
A. Parand, Iran
M. Shokoohi-Yekta, S. Salem

P-20-09 Effects of cognitive-behavioral stress management on parent-child relationship and mental health of mothers of children with ADHD
A. Parand, Iran
M. Shokoohi-Yekta

P-20-10 Eye movement and cognitive training in children with Attention Deficit Hyperactivity Disorder
J. Sarzynska, Poland
A. Orylska, H. Lubanski

P-20-11 Attention training in children with Attention Deficit Hyperactivity Disorder
J. Sarzynska, Poland

P-20-12 Incredible years parent training program in ADHD: Parents attendance and satisfaction
M. J. Seabra-Santos, Portugal
M. F. Gaspar, A. Azevedo, T. Homem, M. Pimentel

P-20-14 To utilise wraparound process in a combined health/education initiative (EdWrap) in the management of children presenting with major behavioural/learning problems in local schools
N. Woolfield, Australia
W. Chan, P. Cooper

Scientific Programme – Friday, 27 May 2011

P-21 Guided Poster Tour

14.30–16.00 h Main Foyer

Non pharmacological treatment: Adults

Chairpersons: A. Philipsen, Germany
S. Sprich, USA

P-21-01 Micronutrients reduce stress and anxiety in adults with ADHD after a 7.1 earthquake

A. P. Julia Rucklidge, New Zealand
A. Boggis, J. Johnstone, R. Harrison

P-21-02 First results of the COMPAS group (comparison of Methylphenidate and psychotherapy in adult ADHD study)

A. Philipsen, Germany
S. Matthies, M. Colla, S. Groß-Lesch, T. Jans, E. Sobanski, B. Alm, M. Huss, B. Kis, M. Roesler, E. Graf

P-21-03 The hero with a million faces: Narrative schema realignment in adult ADHD

I. Szpindel, Canada

P-21-04 The effects of the French version of the community parent education program for families of preschoolers with behaviour problems: A pilot study

N. Leblanc, Canada
L. Ben Amor, P.-A. Desmarais, L. Archambault, R.-C. Duval, P. Bouchard, J. Martel, M. Simoneau

P-21-05 A randomized controlled study of a manualised cognitive behavioral treatment for medicated adults with ADHD

B. Emilsson, Iceland
G. Gudjonsson, J. F. Sigurdsson, G. Baldursson, H. Olafsdottir, E. Einarsson, S. Young

P-21-06 Multimodal treatment and coaching in ADHD – development of an advanced training program

P. Greven, Germany
J. Irmscher

P-21-07 ADD & loving It?! And www.totallyadd.com: The new media that transforms psychoeducation in ADHD

U. Jain, Canada
R. Green, A. Green

P-21-08 ADHD adults – incidence of personality disorder and response to treatment with Methylphenidate

F. Reimherr, USA
J. L. Olsen, B. Marchant, R. J. Robison, C. Pommerville, E. D. Williams, C. Halls

15.30–16.00 h

Coffee Break

HT-08

Hot Topic Symposium

16.00–17.30 h

Hall 2

Next steps towards empirically supported psychosocial treatments for adult ADHD

Chairpersons: A. Philipsen, Germany
S. Sprich, USA

HT-08-01 Treatment of adults with ADHD: CBT only versus medication and CBT

L. Hechtman, Canada

HT-08-02 Comparison of CBT to relaxation with educational support for residual ADHD in adults

S. Sprich, USA

HT-08-03 DBT-based treatment in adult ADHD

A. Philipsen, Germany

HT-08-04 Cognitive-behavioral treatment for adult ADHD: Targeting executive dysfunction

M. Solanto, USA

Scientific Programme – Friday, 27 May 2011

HT-09 Hot Topic Symposium

16.00–17.30 h Hall 6

KFO 125 ADHD

Chairpersons: K.-P. Lesch, Germany
T. Renner, Germany

HT-09-01 Familial investigations in ADHD
T. Renner, Germany

HT-09-02 Emotional-motivational deficits in ADHD
A. Conzelmann, Germany

HT-09-03 Imaging genetics in ADHD – neurophysiological endophenotypes
A.-C. Ehli, Germany

HT-09-04 Genome-wide screening approaches: Towards identification of pathogenetic mechanisms
K.-P. Lesch, Germany

HT-10 Hot Topic Symposium

16.00–17.30 h Hall 4/5

Emotional symptoms in ADHD: Part of the disorder?

Chairpersons: F. Reimherr, USA
M. Rösler, Germany

HT-10-01 Mood variability in adults with ADHD
P. Asherson, United Kingdom

HT-10-02 Emotional symptoms in children and adolescents with ADHD
T. Banaschewski, Germany

HT-10-03 The concept of emotional symptoms as defined by the Utah criteria of ADHD
F. Reimherr, USA

HT-10-04 Different psychopathological dimensions in adult ADHD
R.-D. Stieglitz, Switzerland

HT-11 Hot Topic Symposium

16.00–17.30 h Hall 3

International ADHD treatment guidelines for childhood, adolescence and adulthood

Chairpersons: J. Thome, Germany
B. Millet, France

HT-11-01 Guidelines in Francophone and Eastern European countries
B. Millet, France

HT-11-02 Guidelines in Mediterranean and Latin countries, Asia and Africa
J. A. Ramos-Quiroga, Spain

HT-11-03 Guidelines in nordic and German-speaking countries
R. Wandschneider, Germany

HT-11-04 ADHD guidelines in Anglophone countries
J. Thome, Germany

HT-12 Hot Topic Symposium

16.00–17.30 h Hall 7

ADHD and conduct disorder from childhood to adulthood

Chairpersons: C. Freitag, Germany
E. Barker, United Kingdom

HT-12-01 Co-morbid disorders of childhood ADHD
M. Romanos, Germany

HT-12-02 Cortisol awakening response in children with ADHD with and without oppositional defiant disorder or conduct disorder
C. Freitag, Germany

HT-12-03 Genome-wide association analysis of conduct disorder in an ADHD background
R. Anney, Ireland

HT-12-04 Co-occurring problems of early onset persistent, childhood limited, and adolescent onset conduct problem youth
E. Barker, United Kingdom

Scientific Programme – Friday, 27 May 2011

YS-01 Young Scientist Session

16.00–17.30 h

Hall 8

Young Scientist Award Session I

Chairpersons: M. Weiss, Canada
E. Taylor, United Kingdom

YS-01-01 Different executive function profiles in children and adolescents with subtypes of ADHD

E. W. Skogli, Norway

YS-01-02 Attention Deficit Hyperactivity Disorder symptoms and environmental adversity in a prospective population study of preschoolers

E. Paliokosta, United Kingdom

YS-01-03 Symptoms of ADHD and psychopathy in perpetrators—A factor-analytic approach

S. Bouregghda, Germany

W. Retz, M. Rösler

YS-01-04 EEG parameters during working memory task and response inhibition differentiate between medicated and medication naive children and adolescents with ADHD

J. Geissler, Germany

Please visit the

Technical Exhibition in the Central Lobby on the Lobby Level

Opening hours

Thursday	26 May 2011	15.00 – 20.00 h
Friday	27 May 2011	09.00 – 17.00 h
Saturday	28 May 2011	09.00 – 17.00 h
Sunday	29 May 2011	09.00 – 13.00 h

Scientific Programme – Saturday, 28 May 2011

ES-04 Educational Seminar

07.45–08.30 h Hall 4/5

Diagnostic assessment of ADHD in adults using the new structured DIVa 2.0

Chairperson: S. Kooij, The Netherlands

ES-05 Educational Seminar

07.45–08.30 h Hall 6

Neurofeedback in the doctor's office

Chairperson: U. Strehl, Germany

ES-06 Educational Seminar

07.45–08.30 h Hall 7

Differential diagnosis of adult ADHD

Chairpersons: E. Sobanski, Germany
C. Jacob, Germany

ES-07 Educational Seminar

07.45–08.30 h Hall 8

Psychometric assessment of adult ADHD

Chairpersons: A. Philipsen, Germany
R.-D. Stieglitz, Switzerland

ME-04 Meet the Experts

07.45–08.30 h Salon 11/12

Guidelines

Expert: E. Taylor, United Kingdom

ME-05 Meet the Experts

07.45–08.30 h Salon 13/14

ADHD over the lifetime

Expert: R. G. Klein, USA

ME-06 Meet the Experts

07.45–08.30 h Salon 15/16

Treatment of adult ADHD

Expert: M. Weiss, Canada

Please book your ticket for the Educational Seminar and the Meet the Experts-Session in advance at the registration counter due to limited number of participants. Only valid in combination with the congress registration fee.

Fee per course: EUR 30

PS-03 Plenary Session

08.30–10.30 h Hall 2

Course, differential diagnosis and co-morbidity of ADHD

Chairpersons: U. Lehmkuhl, Germany
S. Faraone, USA

PS-03-01 ADHD and Borderline personality disorder
A. Fossati, Italy

PS-03-02 ADHD and autism
C. Freitag, Germany

**PS-03-03 ADHD and deficient emotional re-
gulation**
S. Faraone, USA

PS-03-04 ADHD and antisocial behaviour
S. Young, United Kingdom

10.30–11.00 h

Coffee Break

PCD-01 Pro-Con-Debate

11.00–12.30 h Hall 2

The psychostimulant is not dangerous for the patients

Moderator: E. Taylor, United Kingdom

PCD-01-01 Proponent
L. Greenhill, USA

PCD-01-02 Opponent
K. W. Lange, Germany

12.00–14.00 h

Lunch Break

Scientific Programme – Saturday, 28 May 2011

P-22 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Diagnosis: Children and adolescents II

Chairpersons: C. Bachmann, Germany
S. Walitza, Switzerland

P-22-01 Just fuzzy kids or ADHD-kids? Diagnostic utility of questionnaires and PC-tests tapping executive functions for ADHD subtyping

M. Schoefl, Austria
L. Kaufmann, D. Kloo

P-22-02 ADHD or bipolar disorder-survey of cultural differences in diagnosis between Germany and the USA

G. C. Teschke, Germany

P-22-03 The development of screening scales for Attention Deficit Hyperactivity Disorder (ADHD) in Thai children and adolescents age 3-18 years

C. Pornnoppadol, Thailand
V. Piyasilp

P-22-04 Reliability and validity of turgay DSM-IV based disruptive behavior disorders rating scale teacher and parent forms

E. S. Ercan, Turkey
E. Ercan, R. Kandulu, E. Uslu, C. Aydin

P-22-05 Is DSM-IV based ADHD self report scale valid and reliable tool for 8 years children?

E. Ercan, Turkey
E. S. Ercan, R. Kandulu, E. Uslu, C. Aydin

P-22-06 Prevalence of Attention Deficit Hyperactivity Disorder in school-aged children of a poor Brazilian community

M. Arruda, Brazil
M. V. Moura-Ribeiro, J. H. Golfeto, M. E. Bigal, G. Polanczyk

P-22-07 Impact of the environmental factors on the Attention Deficit Hyperactivity Disorder in Moroccan children

F.-Z. Azzaoui, Morocco
H. Hami, A. Ahami

P-22-08 The latent class analysis of subclinical ADHD symptoms in parent and teacher report

A. Kóbor, Hungary
Á. Takács, R. Urbán, V. Csépe

P-22-09 Neuropsychological profiles of adolescents with childhood Attention Deficit Hyperactivity Disorder

F. Cuhadarolu, Turkey
G. Evinc, T. Cak, G. Dinc, Z. Tüzün, C. Esra

P-22-10 Comparison of behavior descriptions between ADD / ADHD diagnosis and innovators using Kirton's Adaption-Innovation (KAI) theory

C. Winton Brodeur, USA
C. Ritzen Kem

P-23 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Diagnosis: Adults

Chairpersons: W. Retz, Germany
R.-D. Stieglitz, Switzerland

P-23-01 Comorbidity, attachment and identity in adolescents with childhood Attention Deficit Hyperactivity Disorder

F. Cuhadaroglu Cetin, Turkey
H. T. Cak, G. Senses Dinc, Z. Tuzun, G. Evinc, E. Cop

P-23-02 Are there differences between patients and close relatives evaluating retrospectively Attention Deficit Hyperactivity Disorder (ADHD) psychopathology in childhood? – A study using the short version of the Wender Utah Rating Scale (WURS-k)

J. Buchli-Kammermann, Switzerland
R.-D. Stieglitz

P-23-03 A screening scale for adult Attention-Deficit Hyperactivity Disorder: Sensitivity, specificity and cut-off score data of Turkish form ASRS

S. Dogan, Turkey
B. Oncu, G. Varol-Saracoglu

P-23-04 Psychometrics of the German short version of the Brown ADD scales

C. Häußinger, Germany
U. Ruhl, I. Hach

© 2011 Blackwell Publishing Ltd *Journal of Internal Medicine* 270: 103–111

P-23-05		P-24	Guided Poster Tour
	Quality rather than quantity of symptomatic criteria for the diagnosis of adult ADHD I. Szpindel, Canada A. Turgay	14.30–16.00 h Main Foyer Co-morbidity: Children and adolescents III Chairpersons: H.-C. Steinhausen, Switzerland V. Jucksch, Germany	
P-23-06	Developing a South African self-report ADHD questionnaire A. Burke, South Africa A. Burke, T.-L. Austin	P-24-01	A clinical study of temperament, phenomenology and psychosocial factors in child and adolescents of disruptive behaviour disorders P. Kumar, India M. Bhatia, V. Agarwal, D. Verma
P-23-07	Developing programs for physicians to diagnose and treat adults with ADHD L. Hechtman, Canada J. Sadek, L. Jerome, U. Jain, M. Weiss, D. Smith, A. Vincent	P-24-02	ADHD-related symptoms and intellectual disabilities D. Macesic-Petrovic, Serbia J. Kovacevic, D. Lazic, L. Puskas
P-23-08	Psychometric properties of the ASRS in a general population: findings from the ChiP-ARD study H. Caci, France V. Oliveri, K. Dollet	P-24-03	Written production characteristics of children with Attention Deficit Hyperactivity Disorder À. Mies, Spain E. Jurado, A. Fornieles, M. Quintana
P-23-09	Neural basis of decision making and reward: Disentangling euthymic patients with bipolar disorder from adults with ADHD A. Ibáñez, Argentina A. Petroni, H. Urquina, M. Cetkovich, T. Torralva, F. Torrente, S. Báez, S. Strejilevich, M. Sigman, A. Lischinsky, F. Manes	P-24-04	Performance evaluation of children with ADHD in reading / writing and math skills with Academic Performance Test –APT F. F. Dias, Brazil M. C. Miranda, L. F. Coelho, S. Rizzutti, S. M. M Palma, M. Muszkat, R. Fígaro, O. F. A Bueno
P-23-10	The symptoms of Attention Deficit Hyperactivity Disorder in the parents of the children with ADHD S. Simsek, Turkey C. Gokcen, E. Fettahoglu	P-24-05	Differences in brain dynamics of ADHD children with and without comorbidity of learning disability P. Adibpour, Iran S. Farahibozorg, N. Sadoughi, R. Rostami, M. Ahmadelou
P-23-11	Evolution of the CADDRA Canadian ADHD practice guidelines-user interface rationale U. Jain, Canada M. Weiss, L. Hechtman, D. Smith, D. Quinn, G. Farrelly, J. Sadek, A. Vincent	P-24-06	Sleep disturbances in children with Attention Deficit Hyperactivity Disorder A. A. Joseph, India M. Mehta, R. Sagar, G. Shukla
P-23-12	Criterion validity of an Attention Deficit Hyperactivity Disorder (ADHD) screening list for screening ADHD in older adults E. Semeijn, The Netherlands M. Michielsen, H. Comijs, A. Beekman, D. Deeg, S. Kooij	P-24-08	Comorbid autism and ADHD: Parent stress and coping D. Hamilton, Australia J. Whelan

Scientific Programme – Saturday, 28 May 2011

P-24-09 The features of the syndrome of the ADHD (Attention Deficit and Hyperactivity Disorders) at children with schizotypal disorder

M. Kalinina, Russia
G. Kozlovskaya

P-25

Guided Poster Tour

14.30–16.00 h

Main Foyer

Co-morbidity: Adults II

Chairpersons: C. Jacob, Germany
M. S. Stoy, Germany

P-25-01 ADHD and axis I disorders

U. Ruhl, Germany
C. Häußinger, I. Hach

P-25-02 Comorbid mood and anxiety disorders in adult ADHD patients

D. Meshkat, Austria
A. Kutzelnigg, C. Eckert, A. Konstantinidis, S. Kasper

P-25-03 ADHD and axis II disorders

I. Hach, Germany
C. Häußinger, U. Ruhl

P-25-04 The accompaniment of inattention with daily excessive sleepiness among individuals with attention deficit disorder or Attention Deficit Hyperactivity Disorder

S. Shirataki, Japan
S. Moriyasu, Y. Idehara

P-25-05 Sleep in adults with Attention Deficit Hyperactivity Disorder (ADHD) of the predominantly inattentive (ADHD-I) and combined (ADHD-C) subtypes

R. Yoon, Canada
U. Jain, C. Shapiro

P-25-06 Sports and movement addiction in adolescents with ADHD – is this an existing differential diagnosis? Review of the literature in sports psychiatry

O. Bilke-Hentsch, Switzerland
M. Schmelzle

P-25-07 Personality traits in a small sample of adults with ADHD: Evaluation with temperament and character inventory, revised (TCI-r) and the NEO-Personality Inventory, revised (NEO-PI-R)

C. S. Miguel, Brazil
M. Klein, M. A. Gobbo, M. A. Silva, L. C. Monteiro, T. M. Alves, M. Louza

P-25-08 Emotional empathy and suicidal ideation in adult ADHD

A. Lischinsky, Argentina
F. Torrente, T. Torralva, F. Manes, E. Gleichgerricht

P-26

Guided Poster Tour

14.30–16.00 h

Main Foyer

Biomarker candidates

Chairpersons: M. Romanos, Germany
R. Taurines, Germany

P-26-01 The voice of ADHD – vocal acoustic biomarkers in ADHD

D. Langner, Germany
J. Langner, L. Gentschow, P. Kunze, E. Ahlers, M. Colla

P-26-02 Can quantitative EEG (QEEG) measures be used as objective indices in the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in adults? – Preliminary study in a Hungarian clinical sample of adults with ADHD

V. Simon, Hungary
P. Czobor, L. Tombor, S. Papp, S. Komlosi, B. Kakuszi, B. Szuromi, L. Balogh, A. Angyalosi, D. Kovács, I. Bitter

P-26-03 An electroencephalographic biomarker separated patients with Attention Deficit Hyperactivity Disorder into two subgroups with significantly different clinical profiles

S. Snyder, USA
T. Rugino, M. Hornig, B. Daviss, E. Tsai, T. Lock, G. Marsella, R. Davis, R. Scheffer, R. Williams, K. McBurnett

- P-26-04** **Examining the feasibility of N200 as an endophenotype candidate in a genetic isolate of familial type ADHD**
M. A. Garcia-Barrera, Canada
N. Trujillo-Orrego, C. B. Holroyd, D. A. Pineda
- P-26-05** **Investigation of brainstem dysfunction in ADHD – ABR changes and medication effects**
S. Nielzén, Sweden
J. Källstrand
- P-26-06** **Alterations in the function of hypothalamic-pituitary-thyroid axis in children with psychiatric disorders**
M. Dabkowska, Poland
- P-26-07** **The objective measurement of the activity in Attention Deficit Hyperactivity Disorder children**
M. Dabkowska, Poland
T. Pracki, D. Pracka
- P-26-08** **AQT cognitive speed and processing efficiency differentiate adults with and without ADHD: A preliminary study**
N. P. Nielsen, Denmark
E. H. Wiig
- P-26-09** **Use of a virtual classroom in a french population: A comparative study between children with ADHD and control children**
S. Bioulac, France
S. Kedziora-Lallemand, P. Philip, C. Fabrigoule, M. Bouvard
- P-26-11** **Psychometric properties of a self report version of the Wender Reimherr Adult Attention Deficit Disorder scale**
F. Reimherr, USA
B. Marchant, E. D. Williams, R. J. Robison, C. Halls, C. Pommerville
- P-26-12** **Measuring restlessness and focus in the context of everyday life in Adults with Attention Deficit Hyperactivity Disorder, before and after treatment with psycho-stimulant medication**
C. Skirrow, United Kingdom
Y. Malliaris, P. Asherson

P-27

Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Epidemiology: Children and adolescents III

Chairpersons: K. W. Lange, Germany

E. van Den Ban, The Netherlands

P-27-01

A different look at the prevalence of Attention Deficit Hyperactivity Disorder and epilepsy

R. Cohen, Israel

Y. Senecky, R. Raz, G. Chodick, V. Shalev,

A. Shuper, D. Inbar, Y. Senecky

P-27-02

Examining the relationship between Attention Deficit Hyperactivity Disorder and overweight in children and adolescents – results from the BELLA-study

B. Sawitzky-Rose, Germany

M. Erhart, N. Wille, B. Herpertz-Dahlmann,

H. Hölling, U. Ravens-Sieberger

P-27-03

A community-based longitudinal controlled cohort study of children with ADHD

D. Efron, Australia

E. Sciberras, J. Nicholson, V. Anderson, P.

Hazell

P-27-04

Attention Deficit and Hyperactivity Disorder in turkish preschool children

S. S. Basgul, Turkey

S. Saltik, A. Beyhun

P-27-05

Attention problems and other psychosocial issues among junior high school students in Japan

H. Ozawa, Japan

N. Nakazawa, Y. Kusumoto, R. Iwanaga,

A. Imamura

P-27-06

Does one out of seven nine-year old boys suffer from ADHD? The increasing administrative prevalence of ADHD in Germany, 2003–2009

M. Schlander, Germany

O. Schwarz, G.-E. Trott, T. Banaschewski,

W. Scheller, M. Viapiano, N. Bonauer

Scientific Programme – Saturday, 28 May 2011

- P-27-07** **The direct cost of Attention Deficit Hyperactivity Disorder (ADHD) in Germany – An age and gender specific analysis**
M. Schlander, Germany
O. Schwarz, G.-E. Trott, M. Viapiano, N. Bonauer, W. Scheller
- P-27-08** **Breastfeeding and parafunctional oral habits in children with Attention Deficit Hyperactivity Disorder: A preliminary report**
O. Sabuncuoglu, Turkey
A. C. Oengul, A. Bıkmazer
- P-27-09** **Maternal rejection, family and cognitive factors: Modeling aggression in children with ADHD**
E. Ercan, Turkey
E. S. Ercan, B. Kabukçu Basay, T. Uysal
- P-27-10** **Are psychostimulants overprescribed in Brazilian school-aged children? A nationwide study**
M. Arruda, Brazil
M. V. Moura-Ribeiro, J. H. Golfeto, M. E. Bigal, G. Polanczyk
- P-27-11** **Accident proneness among youth treated with ADHD medication**
E. van Den Ban, The Netherlands
P. Souverein, W. Meijer, H. van Engeland, H. Swaab, T. Egberts, R. Heerdink

P-28

Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Epidemiology: Children and adolescents IV

Chairpersons: A. Ludolph, Germany
T. Renner, Germany

- P-28-01** **Difference in Internet uses between normal adolescents and ADHD**
C. Arrizabalaga, Spain
A. Aierbe Barandiarana, M. C. Medrano Samaniego

- P-28-03** **ADHD and the family context as a mediating variable and modulating**
J. M. Garcia Cruz, Spain
M. Rodriguez Ruiz, I. Iraurgi Castillo, J. A. Fernandez de Legaria, E. Perez Fernandez de Landa, T. Sota Leiva, I. Ocio Ocio, M. Landabaso Vazquez, J. M. Jimenez Lerma, J. Caceres Carrasco
- P-28-05** **Child sexual abuse and ADHD**
A.-K. Koch, Germany
W. Retz, S. Bouregghda, M. Rösler, P. Retz-Junginger
- P-28-06** **Symptoms of adult Attention Deficit Hyperactivity Disorder and stress in Korean soldiers**
C.-S. Lee, Republic of Korea
- P-28-07** **Public health issues in ADHD Brazilian children**
S. M. Motta Palma, Brazil
D. M. Cruz, E. Rosangela
- P-28-08** **Attention-Deficit/Hyperactivity as factor of socially unacceptable behaviour**
N. Kepes, Bosnia and Herzegovina
- P-28-09** **Prevalence and risk factors for Attention Deficit Hyperactivity Disorder in Brazilian school-aged children – A nationwide study**
M. Arruda, Brazil
M. V. Moura-Ribeiro, J. H. Golfeto, M. E. Bigal, G. Polanczyk

P-29

Guided Poster Tour

14.30 – 16.00 h

Main Foyer

Epidemiology: Adults II

Chairpersons: E. Sobanski, Germany
M. Muenke, USA

- P-29-01** **Prevalence of ADHD and psychiatric comorbidity in adults attended in a Spanish mental health unit**
K. Knecht, Spain
T. Blanch, R. De Álvaro, V. Ferreres, N. Castillo, F. Romero, V. Balanzá

Scientific Programme – Saturday, 28 May 2011

P-29-02	Epidemiology of Attention Deficit Hyperactivity Disorder in Islamic Azad university students of Markazi Province – center of Iran K. Ganji, Iran M. Asgari, F. Tork	P-29-09	Prescription ADHD stimulant non-medical use in adult substance abusers entering treatment: Early findings from the NAVIPPRO® system E. McNaughton, USA T. Cassidy, S. F. Butler, S. Varughese, L. Russo		
P-29-03	Prevalence of adult Attention Deficit Hyperactivity Disorder (ADHD) in Japan: Results from Hamamatsu epidemiological survey M. Ohnishi, Japan K. Nakamura, S. Uchiyama, K. Takebayashi, K. Osumi, M. Tsujii, N. Mori	P-29-11	ADHD and pathological gambling J. Ringling, Germany W. Retz		
P-29-04	Pre- and perinatal risk factors in adult Attention Deficit Hyperactivity Disorder (ADHD): A population-based nested case-control study A. Halmøy, Norway K. Melve, R. Skjærven, J. Haavik	P-29-12	ADHD, Traumatic Brain Injury (TBI) and driving automobiles D. Smith, Canada		
P-29-05	Life quality in ADHD at the elders D. Lazic, Serbia L. Puskas, R. Ristic-Dimitrijevic, M. Nenadovic, J. Kovacevic, D. Macesic-Petrovic, J. Karic, S. Marinkovic	<table><tr><td>P-30</td><td>Guided Poster Tour</td></tr></table>		P-30	Guided Poster Tour
P-30	Guided Poster Tour				
P-29-06	ADHD in the elderly – organisation of daily life and emotional problems over the lifespan F. Philipp-Wiegmann, Germany I. Rauber, A. Schmitt, M. Bauer, W. Retz, M. Rösler	14.30 – 16.00 h Life quality I Chairpersons: M. Solanto, USA A. Rostain, USA			
P-29-07	Teachers’ knowledge about Attention Deficit Hyperactivity Disorder (ADHD): The case of Saudi Arabia K. Alkahtani, Saudi Arabia	P-30-01	Comparing senses of competence, depression and parental attachment in mothers of ADHD children with mothers of normal children E. Abdollahian, Iran S. Yousefi		
P-29-08	Nonmedical use and diversion of specific ADHD stimulants among U.S. adults aged 18-49: A national internet survey S. Varughese, USA T. A. Eaton, S. F. Butler, S. H. Budman, T. Cassidy, L. Russo	P-30-02	Quality of life in Brazilian children with Attention Deficit Hyperactivity Disorder combined type E. Barbante Casella, Brazil J. Marques, J. Goulardins, M. Periotti, S. Pacheco, T. Freire, U. Reed		
		P-30-03	Experience and perception of ADHD: Impacts on coping in private and work life C. Bonnes, Germany		

Scientific Programme – Saturday, 28 May 2011

P-30-04	Attention Deficit Hyperactivity Disorder is associated with impairment in everyday life as reported by parents of affected children: Results of the European Lifetime Impairment Survey H. Caci, France P. Asherson, M. Doepfner, R. Donfrancesco, S. V. Faraone, M. Fitzgerald, A. Hervas, T. Redston, D. Weber, A. Woods	P-30-12	Developing a needs assessment instrument for students with attention-related difficulties in higher education T. Takahashi, Japan M. Iwabuchi
P-30-05	Stigmatization in patients with Attention Deficit Hyperactivity Disorder A. B. Fürmaier, The Netherlands A. K. Müller, L. Tucha, J. Koerts, K. W. Lange, O. Tucha	P-30-13	Impairments caused by AD(H)D – different assessments by doctor and parents H. Niederhofer, Germany B. Mueller
P-30-06	Relation of inattention and hyperactivity-impulsivity with children's self-efficacy beliefs M. Gambin, Poland M. Pudlo, M. Swiecicka	P-31	Guided Poster Tour
P-30-07	Life with ADHD children: Mother's voice P. Gera, India	14.30–16.00 h	Main Foyer
P-30-08	Assessment of quality of life in adult patients with Attention Deficit Hyperactivity Disorder (ADHD) I. Jansen, Germany M. Loewer, J. Schulte-Mäter, B. Feige, A. Philipsen	Life quality II Chairpersons: R. G. Klein, USA M. Weiss, Canada	
P-30-09	Quality of life in children with Attention Deficit Hyperactivity Disorder, before and during pharmacotherapy A. Kesic, Serbia A. Lakic, D. Stevanovic	P-31-01	Parental experiences of diagnosis and treatment of Attention Deficit Hyperactivity Disorder in children: Results from the European Lifetime Impairment Survey A. Hervas, Spain P. Asherson, H. Caci, M. Doepfner, R. Donfrancesco, S. V. Faraone, M. Fitzgerald, T. Redston, D. Weber, A. Woods
P-30-10	The disorder for deficit of attention with hyperactivity: Quality of life perceived by the patient and his parents G. Marta, Spain N. Rosa, M. Jaume, M. Laura, V. Montse	P-31-02	Quality of life, functionality and adverse life events among adult patients with ADHD attended in a Spanish mental health unit K. Knecht, Spain F. Romero, V. Ferreres, N. Castillo, R. De Álvaro, T. Blanch, P. Silvia, A. Ribes, A. I. García, V. Balanzá
P-30-11	The disorder for deficit of attention with hyperactivity: The effect in the context of the family G. Marta, Spain N. Rosa, M. Laura, M. Jaume, V. Montse	P-31-03	Emotional and cognitive responses to interparental conflict in children with Attention Deficit Hyperactivity Disorder L.-Y. Shyu, Taiwan C.-B. Yeh, C.-W. Chang, C.-H. Tu
		P-31-04	Self-esteem, self-efficacy, and resources in adults with ADHD P. E. Newark, Switzerland M. Elsässer, R.-D. Stieglitz

Scientific Programme – Saturday, 28 May 2011

P-31-05	Supporting students with ADHD: Indications for and effectiveness of teaching and exam accommodations D. Baeyens, Belgium L. Van Dyck	P-32	Guided Poster Tour
		14.30–16.00 h	Main Foyer
P-31-06	The efficacy of stress coping skills training on parenting stress of mothers of children with ADHD A. Beh-Pajoo, Iran A. Motevali-Poor	Pathophysiology: Children and adolescents III Chairpersons: S. Bender, Germany F. Zepf, Germany	
		P-32-01	Characteristics of learning planning functions of students with learning disabilities with and without ADHD B. Shrieber, Israel O. Hetzroni
P-31-07	Multidisciplinary allied, government and school support for children diagnosed and treated for Attention Deficit Disorder in Western Australia D. Silva, Australia E. Hagemann, M. Howell, C. Bower	P-32-02	Neuropsychological assessment in a Portuguese sample of children with Attention Deficit Hyperactivity Disorder – combined subtype (ADHD-C) C. Alfaiate, Portugal M. R. Simões, J. B. Fernandes
		P-32-03	Influence of EEG biofeedback on ERPs in Attention Deficit Hyperactivity Disorder children S. Bakhtadze, Georgian M. Janelidze, N. Khachapuridze
P-31-08	Relationship between parent's age and parenting styles in parents of children with Attention Deficit Hyperactivity Disorder T. Baghani, Iran Z. Iarjani, P. Golkarian	P-32-04	Attention Deficit Hyperactivity Disorder: Event-related brain potentials in test go/nogo E. Yakovenko, Russia I. Nikishena, L. Chutko
		P-32-05	A comparative study of ADHD, RD (Reading disable) children's frontal brain cognitive functions with normal children by implementing cognitive assessment system (CAS) S. Najafi, Iran J. Molazade, M. A. Goodarzi, M. R. Taghavi, V. Sadeghi
P-31-09	ADHD service reforms-impact of ADHD nurse specialist role in improving outcomes in ADHD management R. Beets, United Kingdom I. Takon, A. Galloway, W. McClaughlin	P-32-06	Neurocognitive functioning in children with ADHD M. Mehta, India P. Sinha, R. Sagar
		P-32-07	ADHD symptoms modulates the use of spatial and stimulus-response learning and memory strategies in 8-year old children P. Robaey, Canada S. McKenzie, R. Schachar, M. Boivin, G. Dionne, V. Bohbot
P-31-10	Children with ADHD and bullying T. Manovic, Croatia M. Lokas, G. Buljan Flander		
P-31-11	The relationship between severity of child's ADHD symptoms and mother's parenting styles M. Holisaz, Iran M. Cheraghi, F. Fallahi		
P-31-12	Relationship between marital satisfaction and anxiety in mothers of children with Attention Deficit Hyperactivity Disorder Z. S. Larijani, Iran T. Baghani, L. Azhdehfar		

Scientific Programme – Saturday, 28 May 2011

P-32-08	Cognitive performance measured by the stop task in children with ADHD and their non-affected siblings R. Suwwan, Brazil G. Coutinho, J. A. Sergeant, P. Mattos, P. Mattos	P-33-05	Orienting of attention and interference control in children with Attention Deficit Hyperactivity Disorder A. Masumi, Japan S. Okazaki, H. Maekawa
P-32-09	The role of motor control deficiencies in adapting multi-component visual-motor tasks in children with Attention Deficit Hyperactivity disorder C. Yakut, USA	P-33-06	Reaction time variability and cognitive arousal in Attention Deficit Hyperactivity Disorder: A cognitive-EEG investigation C. Cheung, United Kingdom G. McLoughlin, F. Rijdsdijk, P. Asherson, J. Kuntsi
P-32-10	The survey and comparative between correlation in working memory and false memory in students who with and without ADHD H. S. Khademi, Iran H. Alizadeh, H. Asadzadeh	P-33-07	Error and reinforcement processing in medicated and medication-free children with ADHD: An electrophysiological study Y. Groen, The Netherlands O. Tucha, B. Wijers, M. Althaus
P-33	Guided Poster Tour	P-33-08	Boys with ADHD and their mothers: What can we learn from the neuroendocrinology? N. Vuksanovic, Germany C. Kern, K. Zeber, M. Bidlingmaier, J. Borns, K. H. Brisch
14.30 – 16.00 h	Main Foyer	P-33-09	EEG abnormalities in children diagnosed with ADHD by the time of ADHD assessment D. Socanski, Norway A. Herigstad
Pathophysiology: Children and adolescents IV Chairpersons: A. Conzelmann, Germany A.-C. Ehlis, Germany		P-33-10	Classification of ADHD subtypes using independent ERP components M. Aguilar, Spain J. Gomez-Amor, E. Herrera-Gutierrez
P-33-01	Lexical processes in children with Attention Deficit Hyperactivity Disorder: A preliminary event-related brain potentials study P. Gonzalez-Perez, Spain A. Dominguez, D. Beltrán, S. Hernández, A. Quintas, L. Artilles	P-33-11	Study of EEG characteristics in children with Attention Deficit Hyperactivity Disorder I. Khachidze, Georgian M. Gugushvili, V. Maloletnev
P-33-02	Electro-cortical correlates of intra-subject variability in Attention Deficit Hyperactivity Disorder (ADHD) C. Klein, Germany B. Feige	P-33-12	Behavioral and neurophysiological study of attentional and inhibitory processes in ADHD and control children with a continuous performance task S. Baijot, Belgium N. Deconinck, I. Massat, H. Slama, C. Colin
P-33-03	Inherited Pre-frontal cortex (Pfc) disinhibition in Attention Deficit Hyperactivity Disorder (ADHD) adolescents offspring of Alcohol Use Disorder (AUD) parents M. Habeych, USA R. Tarter		
P-33-04	Cortical inhibition and facilitation: Preliminary results of a comparison between children with ADHD and autism A. Kröger, Germany T. Jarczok, C. M. Freitag, S. Bender		

P-34 Guided Poster Tour

14.30–16.00 h Main Foyer

Pathophysiology: Adults II

Chairpersons: D. Brandeis, Switzerland
M. S. Stoy, Germany

P-34-01 Participants with high subclinical ADHD symptoms show reduced suppression in the processing of task-irrelevant stimuli as evidenced by the N170

S. C. Biehl, Germany
A. Niklaus, J. Deckert, M. J. Herrmann

P-34-02 Theta/beta ratio is related to approach motivation in healthy controls but not in adults with Attention Deficit Hyperactivity Disorder

J. Sidlauskaitė, Belgium
R. Wiersema, I. Buyck

P-34-03 Increased rightward low alpha asymmetry in adults with Attention Deficit Hyperactivity Disorder

I. Buyck, Belgium
J. R. Wiersema

P-34-04 Neurophysiological correlates of delinquent behaviour in adult subjects with ADHD

N. Meier, Switzerland
W. Perrig, T. Koenig

P-34-05 Cortical arousal in adults with Attention Deficit Hyperactivity Disorder

A. Edge, South Africa

P-34-06 Assessment of postexcitatory long-interval cortical inhibition in adult Attention Deficit Hyperactivity Disorder

W. Retz, Germany
E. González-Trejo, F. Philipp-Wiegmann, K. Römer, P. Reinert, Y. F. Low, S. Bouregghda, M. Rösler, D. Strauss

P-34-07 Default mode network (DMN) impairments in adults with ADHD and bipolar disorder: Connectivity and variability

P. Barttfeld, Argentina
A. Petroni, H. Urquina, M. Sigman, M. Cetkovitch, T. Torralva, F. Torrente, S. Báez, A. Lischinsky, F. Manes, A. Ibáñez

P-34-08

Cortical deficits in emotion processing for faces in adults with ADHD: Its relation to social cognition and executive functioning

A. Ibáñez, Argentina
A. Petroni, H. Urquina, T. Torralva, F. Torrente, E. Hurtado, R. Guex, S. Báez, M. Sigman, A. Lischinsky, F. Manes

P-34-09

Electrophysiological correlates of inhibition system in adolescents and adults with different levels of inattention, impulsivity, hyperactivity

A. Trembach, Russia
D. Samarskiy, V. Tolokonnikova

P-35

Guided Poster Tour

14.30–16.00 h

Main Foyer

Pharmacological treatment: Children and adolescents III

Chairpersons: A. Rothenberger, Germany
M. Danckaerts, Belgium

P-35-01

Prolonged cognitive improvement of attention and inhibition in children with ADHD treated with OROS Methylphenidate

H. Slama, Belgium
P. Fery, D. Verheulpen, P. Van Bogaert

P-35-02

The place of Methylphenidate in the treatment of ADHD. A Tunisian experience

Z. S. Abbes, Tunisia
S. Othman, F. Charfi, S. Halayem, A. Belhadj, A. Bouden, M. Halyem

P-35-03

Comparison of the efficacy and safety of OROS-methylphenidate and IR-methylphenidate in Turkish children with Attention Deficit Hyperactivity Disorder: A retrospective chart review

E. S. Ercan, Turkey
O. Basay, E. Ercan, B. Kabukcu Basay, C. Aydin

P-35-04

Moderators of one-month treatment response to OROS Methylphenidate in subjects with ADHD in a naturalistic study

O. Oner, Turkey
P. Oner, E. Cop, K. Munir

Scientific Programme – Saturday, 28 May 2011

P-35-05	The clinical impact of switching ADHD patients from concerta® to a second entry product: a pediatric practice review J. van Stralen, Canada	P-36	Guided Poster Tour
		14.30–16.00 h	Main Foyer
		Pharmacological treatment: Children and adolescents IV Chairpersons: R. W. Dittmann, Germany G.-E. Trott, Germany	
P-35-06	Ginkgo biloba extract EGb 761® is effective and safe in the treatment of ADHD in children S. Klement, Germany N. Bock, A. Rothenberger	P-36-01	Compliance with Strattera (atomoxetine) in a patient support programme for Attention Deficit Hyperactivity Disorder in the United Kingdom A. Lenox-Smith, United Kingdom J. Cooper-Jones, N. Savill, S. Cryer, J. Pelton
P-35-07	Atomoxetine response in the inattentive and combined subtypes of Attention Deficit Hyperactivity Disorder: A retrospective chart review E. S. Ercan, Turkey B. Kabukcu Basay, E. Ercan, O. Basay, C. Aydin	P-36-02	Attention Deficit Hyperactivity Disorder, medication and adolescents: What do they have to say about it? J. Monteiro, Portugal M. Pinto, V. Monteiro
P-35-08	The functionality of ADHD comorbid ODD and/or CD children after 6 years: The treatment effect on prognosis E. S. Ercan, Turkey O. Akyol, A. Kutlu, S. Köse, C. Aydin	P-36-04	Risk factors for discontinuation of atomoxetine treatment in Attention Deficit Hyperactivity Disorder (ADHD) D. Shin, Republic of Korea E.-J. Kim
P-35-09	Analysis of effect size in two clinical trials to evaluate the efficacy of lisdexamfetamine dimesylate in children with Attention Deficit Hyperactivity Disorder M. Gasior, USA S. Wigal, C. Richards, J. Gao	P-36-05	Prescription of melatonin in a clinic for severe ADHD A. Sørensen, Denmark P. H. Thomsen, I. R. Møller
P-35-10	ADHD diagnostics and treatment–experiences at a Hungarian psychiatric hospital and clinic for children S. Oláh, Hungary Á. Hajdu, Z. Martsa, A. Bátki, J. Gádoros	P-36-06	Neuroleptic therapy and affective instability of children with ADHD B. Iana, Ukraine M. Igor, V. Olesya
P-35-11	A new approach to the therapy of attention deficiency hyperactivity disorder, affecting neurotransmitter systems of brain I. Komlach, Russia A. Danilov, S. Atalikov	P-36-07	Development of a teaching aid to assist doctors, other health care providers and patients in using medications to treat ADHD A. Vincent, Canada D. Smith
P-35-12	ADHD and drug therapy J. Kovacevic, Serbia D. Lazic, D. Macesic-Petrovic	P-36-08	Use of Methylphenidate in children and adolescents with Attention Deficit Hyperactivity Disorder: A study of 445 cases S. Antoniuk, Brazil M. Wehmuth, M. C. Bromberg

P-36-09	Optimal dosages of OROS Methylphenidate for treatment response in children and adolescents with ADHD; Korean multisite open-label study D. Song, Republic of Korea B.-N. Kim, Y. S. Joung, K.-A. Cheon, D. Shin, Y.-J. Shin, H. J. Yoo, K. Jung	P-37-04	Children treated with pharmacotherapy for Attention Deficit Disorder in Western Australia: Mental health problems and family functioning D. Silva, Australia R. Glauert, S. Houghton, S. Zubrick, B. Jon- geling, M. Cooper, C. Bower
P-36-10	Efficacy of slow vs. fast switching from stimulants to atomoxetine in children and adolescents with ADHD V. Porsdal, Denmark E. Anand, D. Quail, M. Casillas, R. Escobar	P-37-05	Continuous Performance Test (CPT) as a quick instrument to assess the effectiveness of Methylphenidate (MPH) in school age children with ADHD J. Boavida, Portugal S. Nogueira, M. Almeida, E. Fernandes, C. Alfaiate, M. J. Seabra Santos
P-36-11	Raynaud's Syndrome and Methylphenidate: A report of two cases J. L. Fernandez Sastre, Spain R. Agueda, G. Flavio, L. Cristina, P. Diego	P-37-06	Effect of Methylphenidate on sleep parameters in children with ADHD W. S. Seo, Republic of Korea J. Y. Back, H.-M. Sung, T. Y. Choi
P-36-12	Clinical use of clonidine in ADHD management: Report of experience from a specialist ADHD clinic in the East of England I. Takon, United Kingdom R. Beets	P-37-07	An open-label study of Metadata CD® on the improvements of clinical symptoms and neurocognitive functions in Korean children and adolescents with Attention Deficit Hyperactivity Disorder Y. S. Lee, Republic of Korea H. K. Yoo, B. S. Kim, Y. S. Joung, G. H. Bahn, D. H. Song, D. H. Ahn
P-37	Guided Poster Tour		
14.30 – 16.00 h	Main Foyer		
Pharmacological treatment: Children and adolescents V Chairpersons: J. Geissler, Germany J. Newcorn, USA		P-37-08	Monitoring social behavior using the Child Conflict Index in children with ADHD Treated with OROS® Methylphenidate B. Schaeuble, Germany H. L. Starr, R. Armstrong, C. Damaraju, S. Ascher
P-37-01	Survey of clinicians medication monitoring practices, following treatment initiation in children with newly diagnosed ADHD–United Kingdom survey S. Yarney, United Kingdom I. Takon, L. Watts	P-37-09	Effects of OROS® Methylphenidate (MPH) treatment on behavior and performance in children with ADHD with and without Comorbid Learning Disability B. Schaeuble, Germany H. L. Starr, R. B. Armstrong, C. Damaraju, S. Ascher
P-37-02	Assessment of atomoxetine effect in pediatric patients with Attention Deficit Hyperactivity Disorder: A meta-analysis of consistency of 15 clinical trials in 4 geographic regions Y. Tanaka, USA L. Jin, H. Upadhyaya	P-37-10	Pharmacological treatment outcomes in children compared to adolescents with ADHD transitioning onto OROS MPH B. Schaeuble, Germany M. Berek, A. Kordon, F. Mattejat, K. Rettig, M. Djelani
P-37-03	Measuring emotion regulation in children with ADHD: A pilot study of the emotional flanker task V. Van Cauwenberge, Belgium J. R. Wiersma		

Scientific Programme – Saturday, 28 May 2011

- P-37-11** **Changes in functionality and quality of life aspects in children with ADHD after transitioning onto OROS MPH**
B. Schaeuble, Germany
A. Kordon, M. Berek, F. Matthejat, K. Rettig, M. Djelani

P-38 Guided Poster Tour

14.30 – 16.00 h **Main Foyer**

Non pharmacological treatment: Children and adolescents III

Chairpersons: R. Wandschneider, Germany
D. Eich-Höchli, Switzerland

- P-38-01** **The effect of social skill training (SST) for children with Attention Deficit Hyperactivity Disorder (ADHD) and Asperger's Disorder (AD); preliminary study**
Y. S. Kwack, Republic of Korea
J.-h. Shin

- P-38-02** **Roc and ash to the rescue: A web-based cognitive approach to literacy and ADHD**
S. Lim, Singapore
J. L. Kheng, Y. P. Ooi, L. Su, D. S. Sheng Fung

- P-38-03** **Training parents of Indian children with ADHD**
M. Mongia, India
R. Sadhu, M. Mehta, R. Sagar

- P-38-04** **Neurobiofeedback – therapeutic alternative or supplement? Influence of neurobiofeedback on behaviour, impulse control and electroneurophysiology in ADHD children**
E. Cionek-Szpak, Germany
F. Poustka, C. Stadler, N. Panzer, M. Holtmann

- P-38-05** **The effectiveness of group parent management training on behavioral disorders among 4 to 10 year old ADHD children**
P. Houshvar, Iran
S. Zarshenas, F. Behnia, E. Pishyareh

- P-38-06** **Efficacy of multimodal intervention for children with Attention Deficit Hyperactivity Disorder (ADHD) – An Indian study**
R. Gopalan, Malaysia
A. Oommen, S. Srinath

- P-38-07** **Social skills training and parental training plus standard treatment versus standard treatment of children with Attention Deficit Hyperactivity Disorder: The SOSTRA trial**
O. J. Storebø, Denmark
J. Pedersen, M. Skoog, P. H. Thomsen, P. Winkel, C. Gluud, E. Simonsen

- P-38-08** **Psychosocial Interventions Canadian ADHD Practice Guidelines (CAP-Guidelines, 2011): A Consensus- and Evidence-Based, Practical Resource for Physicians Assessing and Treating ADHD across the Lifespan**
G. Farrelly, Canada
U. Jain, L. Hechtman, M. Weiss, D. Quinn, D. Smith, A. Vincent, J. Sadek, L. Jerome

- P-38-09** **The effectiveness of a multi sensory therapeutic program in enhancing language skills for children with Attention Deficit Hyperactive Disorder (ADHD)**
T. El. Sayed Ahmad, Kuwait
T. A. Karim

- P-38-10** **Promising results with a dietary supplement in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children**
B. Hackenberg, Austria
C. Grylli, W. Schuhmayer

- P-38-11** **Sensory stimulation reduces symptoms associated with sensory integration deficiency in Attention Deficit Hyperactivity Disorder children**
H. Haghgoo, Iran
S. A. Hosseini

- P-38-12** **Effects of gum chewing on vigilance in children with ADHD**
L. Tucha, The Netherlands
T. A. Sontag, K. W. Lange, O. Tucha

- P-38-13** **Parent training for preschool ADHD: research protocol for a randomised controlled, multi-center effectiveness trial of the New Forest Parenting Programme in a clinical sample of Danish children**
A.-M. Lange, Denmark

- P-38-14** **Effect of the cognitive remediation at adolescent with ADHD**
M. Bader, Switzerland
N. Hadjikhani, B. Pierrehumbert, S. Leopizzi, O. Halfon

© 2011 Blackwell Publishing Ltd *Journal of Internal Medicine* 270: 105–114 111

- P-38-15** **Attention Deficit Hyperactivity Disorder in children with epilepsy: Response time profile and effect of Methylphenidate**
P. Berquin, France
A. Delignières, E. Bourel-Ponchel, A. Simonot,
L. Querne
- P-38-16** **Concerta® XL treatment for attention-deficit hyperactivity disorder: A retrospective case review of clinical outcomes and treatment choice in a cohort of paediatric outpatients**
L. Pert, United Kingdom
C. Steer

P-39 **Guided Poster Tour**

14.30–16.00 h **Main Foyer**

Experimental Models

Chairpersons: A. Reif, Germany
E. Grünblatt, Switzerland

- P-39-01** **A simple behavioral paradigm to measure impulsive behavior in an animal model of Attention Deficit Hyperactivity Disorder (ADHD), the spontaneously hypertensive rats**
P. Kim, Republic of Korea
I. Campomayor dela Pena, I. Choi, C. S. Choi,
J. H. Ryu, J. H. Cheong, C. Y. Shin
- P-39-02** **Effects of early stress on impulsivity and reward learning in a novel animal model for ADHD**
J. Kunzler, Germany
A. K. Braun, J. Bock
- P-39-03** **Behavioral phenotyping of heterozygous Snap25 knockout mice as a potential model of ADHD**
A. Post, Germany
S. Popp, A. Schmitt, A. Reif, K.-P. Lesch
- P-39-04** **Effects of BLK-030 and BLK-032 in a preclinical model of Attention Deficit Hyperactivity Disorder. Comparison with mazindol, modafinil and haloperidol**
J.-C. Bizot, France
S. David, N. Fery, F. Trovero, M. Lecendreau,
L. Ferrie, B. Fiquadère, E. Konofal

- | | |
|---------|--|
| P-39-05 | <p>The NK1 receptor 'knockout' mouse model of Attention Deficit Hyperactivity Disorder: Effects of d-amphetamine on impaired cognitive performance / response control in the 5-Choice Serial Reaction-Time Task</p> <p>S. C. Stanford, United Kingdom
T. C. Yan, R. K. Weir, J. A. Dudley, E. M. Grabowska, Y. Peña Oliver, T. Ripley, S. P. Hunt, D. N. Stephens</p> |
| P-39-06 | <p>Link between insulin resistance, hypertension and Attention Deficit Hyperactive Disorder</p> <p>E. Grünblatt, Switzerland
J. Bartl, A. Borst, D.-I. Iuhos, P. Riederer, M. Salkovic-Petrisic, S. Walitza</p> |
| P-39-07 | <p>Effect of atomoxetine on tyrosine hydroxylase (TH) in animal model of Attention Deficit Hyperactivity Disorder: Adult male Spontaneously Hypertensive Rat (SHR)</p> <p>S. Moon, Republic of Korea
J. Min, C. Kim, G. Bahn</p> |
| P-39-08 | <p>Long-term oral application of Atomoxetine leads to increased SNAP-25 expression</p> <p>T. Lempp, Germany
S. W. Tönnies, C. M. Freitag, G. Geisslinger, E. Niederberger</p> |
| P-39-09 | <p>Effects of acute and chronic Methylphenidate application on free radical formation in rats</p> <p>H.-W. Clement, Germany
O. Sommer, A. Hoinkes, P. Heiser, E. Schulz</p> |
| P-39-10 | <p>Age dependent effects of Atomoxetine – chronic treatment causes differential alteration of Monoaminergic transporters and postsynaptic proteins in rodents</p> <p>P. T. Udvardi, Germany
S. Liebau, J. Dreyhaupt, J. M. Fegert, T. M. Böckers, A. G. Ludolph</p> |
| P-39-11 | <p>Methylphenidate treatment in the spontaneously hypertensive rat: Influence on Methylphenidate self-administration and reinstatement in comparison with Wistar rats</p> <p>I. Dela Pena, Republic of Korea
H. S. Ahn, J. C. Lee, C. Y. Shin, J. H. Cheong</p> |

Scientific Programme – Saturday, 28 May 2011

P-40 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Miscellaneous I

Chairpersons: O. Tucha, The Netherlands
U. Müller, United Kingdom

P-40-01 Hostility and anger expression at school children with hyperkinetic disorder

I. Martsenkovsky, Ukraine
I. Martsenkovska

P-40-02 Motor learning training decreases depression and helps to free up cognitive resources in older people

N. Trushkova, Italy

P-40-03 Parenting stress in mothers of children with and without Attention Deficit Hyperactivity Disorder (ADHD)

S. Yousefi, Iran
A. Soltanifar, S. Teimouri

P-40-04 Diagnostic indicators for multiple X and Y chromosome disorders in pediatric age

A. Verri, Italy
A. Cremante, F. Clerici, L. Nespoli

P-40-05 Age-related structural vascular changes at persons with cardiovascular risk factors

G. Rozikhodjaeva, Uzbekistan
Z. Ikramova, F. Rozikhodjaeva

P-40-06 Psychiatric disorders among children living in orphanages – experience from Kashmir

Y. Rather, India
M. Margoob

P-40-07 The children living in orphanages in conflict area Kashmir: An exploration of their nurture, nature and needs

Y. Rather, India
M. Margoob

P-40-08 Quality of life assessment: A study among urban and rural elderly of West Bengal

M. Maity, USA
B. Mukhopadhyay

P-40-09

Video-assisted observation of facial expression and neuropsychological QbTest-features in children with ADHD share a curvilinear course and both of them indicate the same optimal methylphenidate dose

H.-J. Kuehle, Germany
P. Rautzenberg, R. Lefering

P-41 Guided Poster Tour

14.30 – 16.00 h Main Foyer

Miscellaneous II

Chairpersons: J. Thome, Germany
F. Reimherr, USA

P-41-01 Different expectations of AD(H)D medication by doctors and patients

H. Niederhofer, Germany
B. Mueller

P-41-02 Quality assured medical care for ADHD patients – first results of an agreement with health insurance funds to improve care in Germany

C. Schaff, Germany
D. Best, K.-P. Grosse

P-41-03 Determining the effectiveness of living skills on reduction of morbid symptoms amongst students contracted Attention Deficit Hyperactivity Disorder

P. Azizi Khereshki, Iran
H. Azizi Khereshki, M. Darini, D. Darini

P-41-04 Positive aspects of Attention Deficit Hyperactivity Disorder

M. Fitzgerald, Ireland

P-41-05 Stress level, life regard and coping strategies of wives with alcoholic husbands in Karnataka India: A basis for an intervention program

S. Lewis, Philippines
J. Lewis, R. Caballero, L. R. Natuel

P-41-06 Challenges in ADHD knowledge transfer

J. Sadek, Canada
L. Hechtman

P-41-07 Attention and executive function using nepsy in sickle cell anemia

N. Argollo, Brazil
S. Nunes, D. L. Miranda, R. Lucena, A. T. Reis,
A. Gramacho, N. Abreu

Scientific Programme – Saturday, 28 May 2011

P-41-08 Research settings in outpatient practices – challenges and prospects

P. Greven, Germany
S. Buchmann, L. Beyer

P-41-09 Soft signs of childhood sexual abuse on the neurocognitive functioning among college women

J. Iglesias, Philippines

P-41-10 Quality of Life and psycho-social outcomes as evolutionary aspects of ADHD

J. Quintero, Spain
M. Loro, N. Garcia Campos, B. Jimenez, K. Tajima, L. De Anta, M. Benitez, D. Zambrano, J. Correas

P-41-11 Outcomes of peripheral social communication clinic in Middlessex, UK for children suspected to have a diagnosis of Autism spectrum disorder

P. Sahare, United Kingdom
L. Murtaza

15.30 – 16.00 h

Coffee Break

HT-13

Hot Topic Symposium

16.00 – 17.30 h

Hall 2

Non-pharmacologic interventions for the treatment of ADHD

Chairpersons: M. Döpfner, Germany
M. Danckaerts, Belgium

HT-13-01 Dietary Interventions in ADHD

J. Buitelaar, The Netherlands

HT-13-02 Effects of family based interventions

M. Döpfner, Germany

HT-13-03 Effects of school based intervention

M. Danckaerts, Belgium

HT-13-04 Effects of Omega 3/6 dietary supplements in ADHD

M. Johnson, Sweden

HT-14

Hot Topic Symposium

16.00 – 17.30 h

Hall 3

Impact of ADHD on the risk for delinquent behaviour

Chairpersons: S. Young, United Kingdom
D. Hay, Australia

HT-14-01 Adult ADHD and pathological gambling

W. Retz, Germany

HT-14-02 Impact of ADHD on behavior disorders in prison inmates

G. Gudjonsson, United Kingdom

HT-14-03 ADHD modulates the risk for reactive violence

M. Rösler, Germany

HT-14-04 Does childhood treatment of ADHD decline the risk for adult antisocial behaviour

H. Soderstrom, Sweden

HT-15

Hot Topic Symposium

16.00 – 17.30 h

Hall 6

Circadian rhythmicity in ADHD patients through life time

Chairpersons: J. Thome, Germany
S. Kooij, The Netherlands

HT-15-01 Changes of circadian behaviour in ADHD patients

S. Kooij, The Netherlands

HT-15-02 Impact of ADHD medication on circadian rhythms and clock gene expression

A. Coogan, Ireland

Scientific Programme – Saturday, 28 May 2011

HT-15-03 **Insomnia and morning/evening preference among ADHD patients compared to healthy individuals and other patients with psychiatric disorders**

B. I. Voinescu, Romania
A. Szentagotai, A. Dobrean

HT-15-04 **CLOCK genes polymorphisms and alterations of CLOCK gene expression in ADHD patients**

J. Thome, Germany

HT-16

Hot Topic Symposium

16.00 – 17.30 h

Hall 4/5

Pharmacoinaging in ADHD

Chairpersons: K. Rubia, United Kingdom
J. Newcorn, USA

HT-16-01 **Discrimination of methylphenidate and atomoxetine in healthy volunteers using fMRI**

M. A. Mehta, United Kingdom

HT-16-02 **Head to head comparison of single dose effects of methylphenidate and atomoxetine in fMRI of ADHD children**

K. Rubia, United Kingdom

HT-16-03 **Head to head comparison of 6 weeks treatment effects of methylphenidate and atomoxetine in fMRI of ADHD children**

J. Newcorn, USA

HT-16-04 **TMS-evoked motor cortex inhibition as biomarker of ADHD severity and effects of methylphenidate and atomoxetine**

D. L. Gilbert, USA

YS-02

Young Scientist Session

16.00 – 17.30 h

Hall 8

Young Scientist Award Session II

Chairpersons: P. Asherson, United Kingdom
R. G. Klein, USA

YS-02-01 **Non-shared environmental effects of birth weight on ADHD symptoms persist into early adolescence. A 10-year longitudinal twin study**

C. Greven, United Kingdom

YS-02-02 **Interactions between self-regulation and aspects of parenting in predicting symptoms of Attention Deficit Hyperactivity Disorder**

A. Lordos, Cyprus

YS-02-03 **Differences in functional connectivity patterns during response inhibition in drug naive children with ADHD**

H. Slama, Belgium

YS-02-04 **Association between dopamine- β -hydroxylase gene and Attention Deficit Hyperactivity Disorder in Han Chinese boys**

N. Ji, People's Republic of China

VS-01

Video Session

16.00 – 17.30 h

Hall 7

Neuro-psychiatric movement disorders in children, adolescents and adults

Chairpersons: A. Warnke, Germany
J. Volkmann, Germany

Scientific Programme – Sunday, 29 May 2011

ES-08 Educational Seminar

07.45–08.30 h Hall 4/5

Therapy of co-morbid disorders in child and adolescent ADHD

Chairpersons: R. Taurines, Germany
T. Renner, Germany

ES-09 Educational Seminar

07.45–08.30 h Hall 6

Therapy of co-morbid disorders in adult ADHD

Chairpersons: E. Sobanski, Germany
J. Krause, Germany

ES-10 Educational Seminar

07.45–08.30 h Hall 7

Dialectical behavioural therapy-based treatment in adult ADHD

Chairpersons: A. Philipsen, Germany
C. Jacob, Germany

ES-11 Educational Seminar

07.45–08.30 h Hall 8

Coaching in adult ADHD

Chairpersons: A. Neuy-Bartmann, Germany
R. D'Amelio, Germany

ES-12 Educational Seminar

07.45–08.30 h Salon 11/12

Molecular neuroimaging in adult ADHD: Implications for the understanding the pathogenesis of ADHD

Chairperson: A. Kutzelnigg, Austria

ES-13 Educational Seminar

07.45–08.30 h Salon 13/14

Evidenced-based treatment of child and adolescent ADHD

Chairpersons: M. Romanos, Germany
T. Jans, Germany

ES-14 Educational Seminar

07.45–08.30 h Salon 15/16

The neurocognitive basis of ADHD—from cognitive dysfunctions to treatment options

Chairperson: M. Colla, Germany

PS-04 Plenary Session

08.30–10.30 h Hall 2

Update on treatment of ADHD in childhood, adolescence and adults

Chairpersons: J. Deckert, Germany
D. Coghill, United Kingdom

PS-04-01 Optimizing individually tailored pharmacotherapy in children and adolescents

D. Coghill, United Kingdom

PS-04-02 ADHD through the life cycle

M. Weiss, Canada

PS-04-03 What do we know about psychotherapeutic treatment in adult ADHD?

A. Philipsen, Germany

PS-04-04 Efficacy of neurofeedback training

D. Brandeis, Switzerland
R. Drechsler

10.30–11.00 h

Coffee Break

PS-05 Plenary Session

11.00–13.00 h Hall 2

Persistence of ADHD: Brain imaging, genetics and treatment

Chairpersons: I. Heuser, Germany
R. G. Klein, USA

PS-05-01 Brain correlates of adult outcome in children with ADHD

F. X. Castellanos, USA

PS-05-02 Using structural neuroimaging to understand clinical outcome in ADHD

P. Shaw, USA

PS-05-03 Attention Deficit Hyperactivity Disorder: From understanding genetics to treatment

M. Muenke, USA

PS-05-04 Novel treatments for ADHD

H. Abikoff, USA

Satellite Symposia

26 MAY 2011

SA-05	Satellite Symposium
--------------	----------------------------

16.00–17.00 h Hall 6

Medical treatment of adults with ADHD

SA-05-01 Efficacy and safety of MPH_ER treatment in adult ADHD – results from the EMMA and QUMEA trials
W. Retz, Germany

SA-05-02 Impact of MPH-ER treatment on emotional dysregulation and functional impairments in adults with ADHD
M. Rösler, Germany

SA-05-03 Medication adherence in adults with ADHD
E. Sobanski, Germany

Organizer: MEDICE Arzneimittel Pütter GmbH & Co. KG

SA-01	Satellite Symposium
--------------	----------------------------

17.00–18.30 h Hall 3

ADHD and adolescents

SA-01-01 Welcome and introductions
T. Banaschewski, Germany

SA-01-02 ADHD in adolescents: Impact, symptoms and co-morbidities/progression
R. W. Dittmann, Germany

SA-01-03 Clinical approaches in the comprehensive treatment of adolescents with ADHD
P. Hill, United Kingdom

SA-01-04 Closing commentary
J. Fuentes, Spain

Organizer: Eli Lilly and Company

27 MAY 2011

SA-02	Satellite Symposium
--------------	----------------------------

13.15–14.15 h Hall 3

ADHD in adolescents: Prognosis, functional outcomes and improving adherence

SA-02-01 Prognosis and functional outcomes in ADHD
J. Buitelaar, The Netherlands

SA-02-02 Respecting patient preferences improving adherence in adolescents
J. Fegert, Germany

Organizer: Janssen Pharmaceutica NV

SA-03	Satellite Symposium
--------------	----------------------------

17.45–18.45 h Hall 3

PUFAs and ADHD – More than an hypothesis?

Chairpersons: M. Döpfner, Germany
T. Banaschewski, Germany

SA-03-01 Efficacy of PUFAs in ADHD alone or in combination with methylphenidate
E. Barragan, Mexico

SA-03-02 PUFAs in ADHD, correlation between fatty acids blood values and clinical response
M. Johnson, Sweden

Organizer: Vifor Pharma-Vifor Ltd.

28 MAY 2011

SA-04	Satellite Symposium
--------------	----------------------------

12.30–14.30 h Hall 3

The diversity of ADHD
from assessment to treatment, moving through the years...

Moderator: P. Salgo, USA
Speaker: D. Coghill, United Kingdom
S. Kooij, The Netherlands
G. Mattingly, USA
D. Quinn, Canada
A. Rothenberger, Germany

Organizer: Shire

ES-01**Educational Seminar****07.45–08.30 h****Hall 4/5****Organisation and carrying out of parent training**

Chairperson: C. Neuhaus, Germany

This parent-training program was developed for parents of children and adolescents with ADHD (and Comorbidities)–knowing very well, that in most families at least one parent has ADHD too. The program will be carried out in a group of 12–14 persons during one weekend, with two follow-up meetings (3 hours). After teaching the parents carefully in the neurobiological background of the disorder all the problems with selfregulation and the specific aspects of developmental pathology they experience in some role-play the effect of positive and negative communication. It is proven, that the kids need rules and structure, but it seems to be ultimately important to communicate with them in a clear, friendly and respectful manner with positive “silent messages” (concerning the modulation of voice and mimic). A specific “behavior management” will be explained. In addition parents get help in analysing the preconditions of a conflict in order to alter the setting the next time, as ADHD very often is simply a problem of misunderstanding.

ES-02**Educational Seminar****07.45–08.30 h****Hall 6****ADHD and substance abuse: Problems and pitfalls in early identification and in treatment**

Chairperson: D. Hay, Australia

Longitudinal data from the Australian Twin ADHD Project indicate that adolescents with ADHD begin to experiment with alcohol, tobacco and marijuana 3–4 years before age-matched controls. How do we identify why this happens, just which young people with ADHD are most at risk and what can we do about this? This presentation will focus on factors within the individual such as conditions comorbid with the ADHD and also on peer and family influences. Successful intervention must go well beyond just treating the ADHD and requires a much more multimodal approach. This will be discussed in the context of the recent Australian and other national guidelines for the management of ADHD. This presentation will offer a review of the clinical problems arising in the treatment of ADHD in patients with substance use disorders: differential diagnosis and comorbidity, treatment planning, choice of medication, treatment for non-abstinent patients, psycho-education, coaching and cognitive therapy.

For optimal results, ADHD treatment will have to be tailored to the needs of the individual patients. The main challenge is integrating adequate ADHD treatment in a global treatment plan, which deals effectively with the substance use disorder, the psychiatric comorbidity and the psychosocial problems.

ES-03**Educational Seminar****07.45–08.30 h****Hall 7****Comorbid disorders or attention-deficit-spectrum disorders? What is the relationship between ADHD and Asperger's syndrome?**Chairpersons: L. Tebartz van Elst, Germany
F. Poustka, Germany

At first glance ADHD and Asperger's syndrome or other high functioning autism spectrum disorders (ASD) seem to be well separated. While patients with ASD do have their core deficits in social communication, perception, and social interaction ADHD patients present with inattentiveness, impulsivity and motor hyperactivity. However in clinical practise there are many patients with ASD who are primarily diagnosed as suffering from ADHD. The reason for this is that many high functioning patients with ASD do have attentional problems which are very similar to those in ADHD. Patients with ASD also often do have problems with impulse control. At the same time patients with classical ADHD also may have severe problems with social perception and competence. In some cases there may be discussions among specialists as to whether a patient should be classified as suffering primarily from ADHD or ASD.

This difficult constellation in clinical practise is topic of this educational seminar. The differential diagnosis between these two entities – which both begin in early childhood – and hallmarks of clinical presentation as well as therapeutic strategies (for example treatment of inattention, impulsivity and aggression in both disorders) will be explored from the perspective of child- and adolescent psychiatry (first talk Prof. Poustka) and adult psychiatry (second talk Prof. Tebartz van Elst).

The issue will be discussed based on case histories. Following the two key note lectures the focus of the seminar will be on case based discussions.

An exchange about differential diagnosis of and differential therapeutic approaches to symptoms like poor social perception and competence, impulsivity, emotional instability, hyperactivity, routines etc. will produce a better insight into how such phenomenological states may be classified and treated in clinical practice.

Educational Goals – Saturday, 28 May 2011

ES-04 Educational Seminar

07.45–08.30 h

Hall 4/5

Diagnostic assessment of ADHD in adults using the new structured DIVa 2.0

Chairperson: S. Kooij, The Netherlands

The structured Diagnostic Interview for ADHD in adults (DIVa 2.0) was developed in 2007 at PsyQ in the Netherlands, and is currently being translated into 12 languages. The English, Norwegian and Dutch version are online available for free, Spanish and Swedish will follow soon (www.divacenter.eu). The instrument uses the DSM-IV criteria for ADHD and gives concrete examples of every criterium in both child- and adulthood in order to facilitate appropriate recognition and endorsement. In this seminar you will be introduced to DIVa 2.0 and learn how to use it in clinical practice.

ES-05 Educational Seminar

07.45–08.30 h

Hall 6

Neurofeedback in the doctor's office

Chairperson: U. Strehl, Germany

Neurofeedback of Slow Cortical Potentials in ADHD Slow cortical potentials are slow shifts of brain activity that are near 0 Hz. They belong to the family of event-related potentials and regulate excitation thresholds. As in ADHD the regulation of excitation thresholds is impaired slow cortical potentials feedback is a viable option for therapy. While neurofeedback protocols of spontaneous oscillations of brain activity are well known, SCP-Feedback is being investigated only in the last couple of years. The aim of this seminar is to convey basic psychophysiological knowledge (EEG and Event related potentials) and to explain training protocols. Finally, evidence base, indications and clinical everyday-life will be discussed.

ES-06 Educational Seminar

07.45–08.30 h

Hall 7

Differential diagnosis of adult ADHD

Chairpersons: E. Sobanski, Germany
C. Jacob, Germany

In the diagnostic set-up of adult ADHD the main clinical problem is no longer differentiating ADHD from normal behavior but differentiating ADHD from other psychopathology. This requires that all ADHD look-alike conditions need to be considered in the evaluation of adult ADHD and viewed as part of the differential diagnosis of ADHD. This educational seminar presents the diagnostic procedures for adult ADHD regarding the evaluation of the most important differential diagnoses. We will discuss how adult ADHD can be differentiated from other psychiatric syndromes including affective and anxiety disorders as well as substance use disorders and personality disorders. We will also refer to general medical and neurological conditions including sleep disorders that can mimic adult ADHD symptoms.

ES-07 Educational Seminar

07.45–08.30 h

Hall 8

Psychometric assessment of adult ADHD

Chairpersons: A. Philipsen, Germany
R.-D. Stieglitz, Switzerland

The diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) in adults is a complex process especially if the disorder was not diagnosed during childhood. Different databases and data sources have to be considered. The seminar provides an overview of general problems of the assessment, the different steps of the diagnostic process and the instruments which can be useful to diagnose them. Available are interviews, self and observer rating scales. Finally some unsolved issues in the assessment of ADHD in adults are discussed.

Educational Goals – Sunday, 29 May 2011

ES-08

Educational Seminar

07.45–08.30 h

Hall 4/5

Therapy of co-morbid disorders in child and adolescent ADHD

Chairpersons: R. Taurines, Germany
T. Renner, Germany

Attention Deficit Hyperactivity Disorder (ADHD) has a high incidence of comorbidities with about two thirds of the patients suffering from other psychiatric disorders during lifetime. Comorbid conditions frequently result in severe impairment of everyday life with considerable functional and psychosocial problems. Thus, considerations on pharmacotherapy of ADHD should include comorbid disorders as, e.g., affective disorders, anxiety disorders or aggressive behaviour. Differential effects of stimulants and atomoxetine, as well as co-medication with other psychotropic drugs will be outlined.

ES-09

Educational Seminar

07.45–08.30 h

Hall 6

Therapy of co-morbid disorders in adult ADHD

Chairpersons: E. Sobanski, Germany
J. Krause, Germany

The treatment of co-morbid disorders in adult ADHD is often complicated and requires sophisticated treatment strategies. This educational seminar discusses treatment strategies for adult ADHD with co-morbid depressive disorders, substance use disorders, anxiety disorders, bipolar disorders and autism with focus on pharmacological interventions.

ES-10

Educational Seminar

07.45–08.30 h

Hall 7

Dialectical behavioural therapy-based treatment in adult ADHD

Chairpersons: A. Philipsen, Germany
C. Jacob, Germany

Due to the fact that co-occurring disorders and psychosocial consequences are often the primary problems in adult ADHD psychotherapy could be beneficial. Because of overlapping features in adult ADHD and borderline personality disorder (particularly deficits in emotion regulation, impulse control, low self esteem and disturbed interpersonal relationships) the psychotherapy is mainly based on the principles dialectical-behavioural treatment (DBT, Linehan, 1993). Cognitive-behavioural treatment (CBT) strategies are mainly integrated to modify maladaptive thoughts which interfere with the therapy (homework, acquirement of new skills). The program has been evaluated in two large RCTs in adult ADHD (Philipsen, Jacob et al.) as well as mother-child pairs (Jans, Warnke et al.) In the educational seminar we will focus on the following topics:–Background and reasons for a structured disorder oriented (group) program based on DBT–Structure and topics of the program (e.g. mindfulness, “chaos and control” strategies) – Current research status – Cases, questions and discussion

Please visit the

Poster Exhibition in the Main Foyer on the Lobby Level

Opening hours

Thursday	26 May 2011	15.00 – 19.00 h
Friday	27 May 2011	09.00 – 17.00 h
Saturday	28 May 2011	09.00 – 17.00 h
Sunday	29 May 2011	09.00 – 13.00 h

Educational Goals – Sunday, 29 May 2011

ES-11**Educational Seminar****07.45–08.30 h****Hall 8****Coaching in adult ADHD**

Chairpersons: A. Neuy-Bartmann, Germany
R. D'Amelio, Germany

Adult ADHD patients often get a good understanding of disease mechanisms and coping strategies. However, they often find it difficult to transfer insights from therapy into daily routine. Here coaching offers a complementary technique. It encompasses an individual problem analysis and interventional strategies, eventually supported by the coach in the personal environment of the patient. Coaching involves management training techniques as well as specific cognitive behaviour therapy. It requires a trained coach with profound knowledge about adult ADHD and its specific problems. As such, coaching transfers experiences and represents an interface from clinical practice to daily routine, targeting a behavioural change in ADHD patients in terms of self discipline, self motivation, and emotional control.

ES-12**Educational Seminar****07.45–08.30 h****Salon 11/12****Molecular neuroimaging in adult ADHD: Implications for the understanding the pathogenesis of ADHD**

Chairpersons: A. Kutzelnigg, Austria
R. Lanzenberger, Austria

So far, the complex mechanisms underlying ADHD are not fully understood. However, genetic, biochemical, pharmacological and molecular studies support the hypothesis that multiple neurotransmitter systems are involved in the pathogenesis of ADHD. Serotonergic neurotransmission may, in addition to dopamine and norepinephrine, play an important role in the aetiology of ADHD. Implications of recent molecular neuroimaging studies, especially on the role of serotonergic and noradrenergic neurotransmission in the pathogenesis of ADHD will be discussed during the educational seminar.

ES-13**Educational Seminar****07.45–08.30 h****Salon 13/14****Evidenced-based treatment of child and adolescent ADHD**

Chairpersons: M. Romanos, Germany
T. Jans, Germany

The treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents comprises a multimodal approach including medication, various types of psychotherapy, education or training, or a combination of treatments. This educational seminar gives an overview on evidence based interventions for ADHD in children and adolescents. Current guidelines for diagnosis and treatment are taken into account. Alternative treatment strategies will also briefly be discussed.

ES-14**Educational Seminar****07.45–08.30 h****Salon 15/16****The neurocognitive basis of ADHD—from cognitive dysfunctions to treatment options**

Chairperson: M. Colla, Germany

Abstract not received.

Please book your ticket for the Educational Seminars in advance at the registration counter due to limited number of participants. Only valid in combination with the congress registration fee.

Fee per course: EUR 30

CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 25 years.

CPO HANSER[®] SERVICE

CONFERENCE – EVENT – DESTINATION – ASSOCIATION MANAGEMENT

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design
- association management

BERLIN

Paulsborner Straße 44
14193 Berlin
fon +49-30-300 669 0
fax +49-30-305 73 91
Email: berlin@cpo-hanser.de

HAMBURG

Zum Ehrenhain 34
22885 Barsbüttel
fon +49-40-670 882 0
fax +49-40-670 32 83
Email: hamburg@cpo-hanser.de

FRANKFURT

Julius-Reiber-Strasse 15a
64293 Darmstadt
fon: +49-6151-428 368 0
fax: +49-6151-428 368 9
Email: frankfurt@cpo-hanser.de

www.cpo-hanser.de



List of Exhibitors and Map

The organizers gratefully acknowledge the support of the following companies and associations (as per May 2011).


Company	Booth No.
Principal Sponsors	
Shire	11
Major Sponsors	
Janssen Pharmaceutica NV	10
Eli Lilly and Company	4
General Exhibitors	
ADHD Europe	18
AHG-Klinik für Kinder & Jugendliche	17
CADDRA	7
HBImed AG	8
W. Kohlhammer GmbH	13
Lexicor Medical Technology LLC	19

Company	Booth No.
MEDICE Arzneimittel Pütter GmbH & Co. KG	14
neuro Conn GmbH	3
Noldus Information Technology	5
Novartis Pharma GmbH	6
Pearson Assessment & Information GmbH	15 a
PhenoSys GmbH	15 b
PROTAC A/S	9
Qbtech AB	1
SensoDetect AB	16
Vifor SA	2
Wisepress Ltd.	12

BRIDGE FOYER

Medical Historical Exhibition on ADHD
ISAAP Congress 2011
World Federation of ADHD

EXHIBITION MAP – Central Lobby



List of Chairpersons and Presenters

A

Abbes, Z. S.	35, 55
Abdollahian, E.	51
Abikoff, H.	63
Adibpour, P.	47
Aguilar, M.	54
Al Ansari, A.	40
Albayrak, Ö.	29
Al-Dakrouy, W.	27
Alfaiate, C.	53
Alizadeh, H.	35
Alkahtani, K.	40, 51
An, L.	32
Anney, R.	29, 43
Antoniuk, S.	29, 56
Argollo, N.	60
Arrizabalaga, C.	50
Arruda, M.	46, 50
Asherson, P.	21, 22, 43, 62
Austin, T.-L.	36
Azevado, A.	40
Azhdehfar, L.	40
Azizi Khereshki, P.	60
Azzaoui, F.-Z.	46

B

Bachmann, C.	46
Bader, M.	58
Baeyens, D.	25, 53
Baghani, T.	53
Baijot, S.	54
Bakhshi, S.	40
Bakhtadze, S.	53
Banaschewski, T.	24, 36, 43, 64
Barbante Casella, E.	51
Barbosa, D.	41
Barker, E.	43
Barragan, E.	22, 32, 64
Barta, C.	27
Barttfeld, P.	55
Basgul, S. S.	49
Beets, R.	53
Beh-Pajooh, A.	53
Ben Amor, L.	33
Bender, S.	21, 53
Benkert, D.	39
Berquin, P.	59
Bhang, S.-Y.	35
Biehl, S. C.	55
Bijlenga, D.	30
Bilke-Hentsch, O.	27, 48

Bioulac, S.	49
Bizot, J.-C.	59
Boavida, J.	57
Bonnes, C.	51
Borregaard, K.	29
Bouregbda, S.	44
Brandeis, D.	55, 63
Buchli-Kammermann, J.	46
Buchmann, J.	22
Buitelaar, J.	24, 61, 64
Burke, A.	27, 47
Buyck, I.	55

C

Caci, H.	32, 47, 52
Cangin, C.	28
Castellanos, F. X.	63
Cavangh, M.	37
Cheung, C.	54
Choi, J.	32
Cho, S.-C.	31, 32
Cionek-Szpak, E.	58
Clement, H.-W.	59
Coelho, L. F.	40
Coghil, D.	63, 64
Cohen, R.	49
Colla, M.	35, 63, 68
Conzelmann, A.	34, 43, 54
Coogan, A.	61
Cucu-Ciuhan, G.	25, 40
Cuhadaroglu Cetin, F.	46
Cuhadarolu, F.	46

D

Dabkowska, M.	34, 49
D'Agati, E.	26
D'Amelio, R.	63, 68
Danckaerts, M.	25, 55, 61
Darini, M.	40
Davenaranand, S.	30
Deckert, J.	63
Dehghan, F.	41
Dela Pena, I.	59
Dias, F. F.	47
Diaz, M.-J.	27
Dietrich, K.	31
Direnfeld, E.	32
Dittmann, R. W.	39, 56, 64
Docet, M. F.	27, 30
Dogan, S.	46
Döpfner, M.	37, 61, 64

Drechsler, R.	35
Drevitska, O.	30
Duguid, A.	27

E

Edge, A.	55
Efron, D.	49
Ehlis, A.-C.	34, 43, 54
Eich-Höchli, D.	22, 58
El. Sayed Ahmad, T.	58
Emilsson, B.	42
Endres, D.	34
Ercan, E.	46, 50
Ercan, E. S.	36, 37, 41, 46, 55, 56
Esteki, M.	40

F

Fallgatter, A.	21, 23, 35
Fallu, A.	38
Faraone, S.	24, 45
Farrelly, G.	36, 58
Fegert, J.	64
Fernandez Sastre, J. L.	30, 57
Figaro, R.	34
Fitzgerald, M.	60
Fleischhaker, C.	37
Fossati, A.	45
Fourlani, E.	32
Franke, B.	21, 24
Freire Barbosa, T.	38
Freitag, C.	26, 43, 45
Fuentes, J.	64
Fürmaier, A. B.	52

G

Gambin, M.	52
Gangadharan, S.	30
Ganji, K.	51
Garcia-Barrera, M. A.	49
Garcia Cruz, J. M.	29, 50
Gasior, M.	39, 56
Geissler, J.	44, 57
Gera, P.	52
Gerlach, M.	22
Gétin, C.	29
Geva, R.	35
Ghahramany, M.	41
Gilbert, D. L.	62
Ginsberg, Y.	30
Gobbo, M. A.	38
Gökçen, C.	30, 36

List of Chairpersons and Presenters

Goll, P.	33	Jerkovic, I.	27	Larijani, Z. S.	53
Gonzalez, N.	32	Ji, N.	62	Lazic, D.	51
Gonzalez-Perez, P.	54	Johnson, M.	40, 61, 64	Leblanc, N.	42
Gonzalez, R.	30	Joseph, A. A.	47	Lee, C.-S.	50
Gopalan, R.	58	Jucksch, V.	34, 47	Lee, Y. S.	57
Goulardins, J.	34	Judge, D.	27	Lehmkuhl, U.	45
Greenhill, L.	24, 45	K		Lemiere, J.	34
Greven, C.	31, 62	Kabukcu Basay, B.	29	Lempp, T.	59
Greven, P.	42, 61	Kalinina, M.	48	Lenox-Smith, A.	56
Groen, Y.	54	Kapitány-Fövény, M.	27	Lensing, M. B.	39
Grünblatt, E.	22, 31, 59	Kaufmann, Y.-A.	28	Lesch, K.-P.	21, 30, 43
Gudjonsson, G.	61	Kawatkar, A.	29	Lewis, S.	60
H		Kaye, S.	22	Lim-Ashworth, N.	26
Haavik, J.	21, 30	Kepes, N.	50	Lim, S.	58
Habeych, M.	54	Kesic, A.	37, 52	Lischinsky, A.	48
Hach, I.	48	Khachidze, I.	54	Li, Z.	31
Hackenberg, B.	58	Khademi, H. S.	54	Lora-Espinosa, A.	28
Haghgoo, H.	58	Kiive, E.	31	Lordos, A.	62
Halmøy, A.	51	Kim, H.-W.	31	Lordou, E.	25
Hamilton, D.	47	Kim, P.	59	Ludolph, A.	22, 36, 50
Hanc, T.	26	Kim, S.-C.	26	M	
Harro, J.	30	Kim, T. H.	36	Macesic-Petrovic, D.	47
Häußinger, C.	46	Klein, C.	54	Ma, I.	34
Hay, D.	22, 24, 61, 65	Klein, R. G.	22, 45, 52, 62, 63	Maier, S.	33
Hechtman, L.	42, 47	Klement, S.	56	Maity, M.	60
Hegerl, U.	24	Knecht, K.	50, 52	Malecki, U.	32
Heinzel, S.	31	Knight, K.	34	Maltezos, S.	33
Heiser, P.	38	Kóbor, A.	46	Manghan, B.	26
Hercigonja-Novkovic, V.	25	Koch, A.-K.	50	Manor, I.	39
Hervas, A.	52	Kohn, M.	36	Manovic, T.	53
Heuser, I.	63	Komlach, I.	56	Manti, F.	26
Hill, P.	64	Konrad, A.	33, 34	Marta, G.	52
Holisaz, M.	53	Konrad, K.	23, 32	Martsenkovsky, I.	60
Hong, S. B.	37	Konstenius, M.	27	Martsenkovska, I.	26
Houshvar, P.	58	Kooij, S.	22, 45, 61, 64, 66	Marx, I.	36
I		Kovacevic, J.	56	Masumi, A.	54
Iana, B.	56	Krause, J.	63, 67	Matthies, S.	36
Ibáñez, A.	47, 55	Krause, T.	40	Mattingly, G.	64
Iglesias, J.	61	Kröger, A.	54	McNaughton, E.	51
Ilarraza, T.	36	Kuehle, H.-J.	60	Mehta, M.	53
Inasaridze, K.	35	Kumar, P.	47	Mehta, M. A.	62
Inna, M.	26	Kunzler, J.	59	Meier, N.	55
Isenberg Bechar, D.	37	Kutzelnigg, A.	37, 63, 68	Meisel, V.	39
J		Kwack, Y. S.	58	Melegari, M. G.	26
Jacob, C.	38, 45, 48, 66	L		Mello, C. B. de	33
Jadidi, M.	40	Lakic, A.	29	Merkt, J.	28
Jain, U.	38, 42, 47	Lange, A.-M.	58	Merwood, A.	31
Jansen, I.	52	Lange, K. W.	45, 49	Meshkat, D.	48
Jans, T.	39, 40, 63, 68	Langner, D.	48	Michielsen, M.	30
		Lanzenberger, R.	68	Mies, Ä.	34, 47
				Miguel, C. S.	48

List of Chairpersons and Presenters

Millet, B.	43	Pizarro, M.	33	Sayce, S.	39
Miranda, M.	41	Plattner, B.	39	Schaeuble, B.	39, 57, 58
Mokros, L.	41	Plichta, M. M.	33	Schaff, C.	60
Mongia, M.	58	Pornnoppadol, C.	46	Schlender, M.	28, 49, 50
Monteiro, J.	56	Porsdal, V.	57	Schleepen, T.	36
Moon, S.	59	Post, A.	59	Schmidt, A.	28
Moreno, A.	33	Poustka, F.	24, 26, 65	Schneekloth, T.	28
Motta Palma, S. M.	50			Schneider, H.	33
Mousa, S.	39	Q		Schneider, M.	38
Muenke, M.	30, 50, 63	Quinn, D.	64	Schoefl, M.	46
Mukhopadhyay, K.	31	Quintero, J.	61	Schwarzkopf, W.	38
Müller, A.	35			Seabra-Santos, M. J.	41
Müller, U.	24, 60	R		Segenreich, D.	26
N		Rahimi, A.	25	Seitz, A.	28
Nafi, O.	29	Ramelli, G. P.	29	Semeijn, E.	47
Najafi, S.	53	Ramos-Quiroga, J. A.	22, 43	Seo, W. S.	57
Nakhai, S.	35	Rather, Y.	60	Shaw, P.	63
Nazar, B. P.	30	Reif, A.	21, 39, 59	Shin, D.	56
Neuhaus, C.	24, 65	Reimherr, F.	42, 43, 49, 60	Shin, M.-S.	35
Neuy-Bartmann, A.	63, 68	Renner, T.	21, 30, 31, 43, 50, 63, 67	Shirataki, S.	48
Newark, P. E.	52	Retz, W.	21, 46, 55, 61, 64	Shrieber, B.	53
Newcorn, J.	57, 62	Rhodes, S.	34	Shyu, L.-Y.	52
Niederhofer, H.	52, 60	Richa, S.	29	Sidlauskaite, J.	55
Nielsen, N. P.	38, 49	Ringling, J.	51	Silva, D.	29, 53, 57
Nielzén, S.	49	Rizzoli-Cordoba, A.	32	Silva, M. A.	35
O		Rizzutti, S.	34	Simon, T.	39
Ocana, A.	38	Robaey, P.	25, 37, 53	Simon, V.	48
Ohnishi, M.	51	Rohde, L. A.	24, 29	Simsek, S.	47
Oláh, S.	56	Romanos, M.	22, 28, 43, 48, 63, 68	Sinha Deb, K.	36
Oner, O.	25, 55	Romstein, K.	25	Skirrow, C.	49
Oner, P.	32	Rösler, M.	21, 24, 38, 43, 61, 64	Skogli, E. W.	44
Othman, S.	29	Rostain, A.	22, 51	Skounti, M.	29
Ozawa, H.	49	Rostami, R.	25	Slama, H.	33, 35, 55, 62
P		Rothenberger, A.	21, 24, 55, 64	Smith, D.	51
Palaniappan, P.	26	Rozikhodjaeva, G.	60	Snyder, S.	48
Paliokosta, E.	44	Rubia, K.	21, 32, 62	Sobanski, E.	45, 50, 63, 64, 66, 67
Palma, S. M. M.	26	Rubio, B.	35	Socanski, D.	54
Paloscia, C.	26, 31, 35	Rucklidge, A. P. J.	42	Soderstrom, H.	61
Parand, A.	41	Ruhl, U.	48	Solanto, M.	42, 51
Pazvantoglu, O.	36	S		Song, D.	57
Periotto, M.	37	Saberi, H.	30	Son, J.	33
Perlov, E.	23	Sabuncuoglu, O.	50	Sørensen, A.	56
Pert, L.	59	Sadek, J.	60	Sorensen, L.	34
Peters, H.	28	Sagar, R.	36	Souza, I.	32
Petrakis, I.	27	Sagutdinova, E.	37	Sprich, S.	42
Peyre, H.	27	Sahare, P.	27, 61	Stanford, S. C.	59
Philipp-Wiegmann, F.	30, 51	Salgo, P.	64	Steinhausen, H.-C.	21, 37, 47
Philipsen, A.	42, 45, 63, 66	Saliba, K.	38	Stieglitz, R.-D.	43, 45, 46, 66
Pinto, M.	37	Sandra, B.	35	Storebø, O. J.	58
		Sarzynska, J.	41	Stoy, M. S.	21, 48, 55
		Sawitzky-Rose, B.	49	Strehl, U.	41, 45, 66
				Ströhle, A.	21

List of Chairpersons and Presenters

Su, L.	34	Tykochinsky, O.	40	Weißflog, L.	31
Suwwan, R.	54			Weiss, M.	22, 44, 45, 52, 63
Syrek, S.	28	U		Wilbertz, G.	33
Sznabowicz, M.	28	Udvardi, P. T.	59	Winton Brodeur, C.	46
Szpindel, I.	38, 42, 47			Wohl, M.	31
		V		Wolf, I.	21, 34
T		Vaithiyam, A.	26	Woolfield, N.	41
Takács, A.	35	Van Cauwenberge, V.	57	Wozniak-Prus, M.	34
Takahashi, T.	52	van de Glind, G.	22, 27		
Takon, I.	57	van Den Ban, E.	49, 50	Y	
Tanaka, Y.	57	van den Brink, W.	22, 27	Yakovenko, E.	53
Taurines, R.	22, 25, 48, 63, 67	van Stralen, J.	56	Yakut, C.	54
Taylor, E.	44, 45	Varughese, S.	51	Yang, L.	37
Tebartz van Elst, L.	23, 24, 33, 65	Verri, A.	60	Yang, S.	21
Teschke, G. C.	46	Vincent, A.	56	Yarney, S.	57
Thome, J.	43, 60, 61, 62	Voinescu, B. I.	62	Yeh, C.-B.	33
Thoumy, A.-L.	27	Volkman, J.	62	Yoo, H.	37, 38
Tiemi Shimizu, V.	34	Vuksanovic, N.	31, 54	Yoon, R.	48
Torgersen, T.	38			Young, S.	45, 61
Trembach, A.	55	W		Yousefi, S.	60
Trott, G.-E.	22, 56	Walitza, S.	24, 26, 46		
Trushkova, N.	60	Wandschneider, R.	43, 58	Z	
Tucha, L.	58	Wang, M.-Y.	29	Zasyekina, L.	26
Tucha, O.	22, 41, 60	Warnke, A.	24, 62	Zepf, F.	21, 39, 53
Tufekci, A.	31	Warnke, M. H.	30		

World Federation of ADHD

Attention Deficit Hyperactivity Disorder

President Prof. Dr. Andreas Warnke, Germany
3rd International Congress on ADHD
From Childhood to Adult Disease



SAVE THE DATE

we look forward meeting you at the

4th International Congress on ADHD
From Childhood to Adult Disease

6 – 9 June 2013, Milan, Italy

- Exchanging information on developments
- Advance the clinical and basic research
- Scientific, scholarly and educational training
- Collaboration with other related professional and lay organisations

www.adhd-congress.org

**Global Head Office and
Congress and Exhibition Office**

CPO HANSER[®]
SERVICE

CPO HANSER SERVICE
Zum Ehrenhain 34
22885 Barsbüttel, Germany
Phone: +49 – 40 – 670 882 0
Fax: +49 – 40 – 670 32 83
Email: adhd@cpo-hanser.de

CONGRESS AND EXHIBITION OFFICE



CPO HANSER SERVICE

Zum Ehrenhain 34

22885 Barsbüttel, Germany

Phone: +49-40-670 88 20

Fax: +49-40-670 32 83

Email: adhd2011@cpo-hanser.de

www.adhd-congress.org